| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Unknown | Unknown | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Unknown | Unknown | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Unknown | Unknown |
Recent Updates
Recently added Catalysts
Cytokinetics, Incorporated$84.87
-1.2 (-1.39%)
C 57Pipeline Score Overvalued Pharma · Commercial
Market Cap
9.57 B
EPS
-6.84
P/E Ratio
-
Value Trade
112.86 M
SEC Financials
Q1 2026Dilution Risk
35%Revenue
19.36 M
R&D Expenses
95.53 M
Operating CF
-145.46 M
Total Assets
1.27 B
Total Liabilities
2.10 B
Equity
-826.57 M
D/E Ratio
12,345
-1.86 %
Week
15.82 %
1 Month
13.61 %
3 Month
21.24 %
6 Month
233.8 %
5 Year
-14.51 %
All Time
Cash Data
Cash Position
818.55 M
Monthly Burn
48.49 M
Runway
14.7 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
1.77 M
52 Week Range
29.81 - 80.20
% held by Insiders
4.17 %
% held by Institutions
111.78 %
Enterprise Value
10.04 B
Total Shares
124.24 M
Short %
14.54 %
Float Shares
120.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cytokinetics, Incorporated
1183Total events
12Upcoming
268Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 12
Aug 28, 2026
T2Timing Guidance
Investor event to discuss Late-Breaking Science results at ESC Congress
Aug 29, 2026
T2Oral Presentation
Aficamten vs. Metoprolol Monotherapy in oHCM According to Pre-Trial Treatment in MAPLE-HCM
TBD
T2FDA Feedback Received
Discussions with FDA and other regulatory authorities regarding ACACIA-HCM results
Event history 1171
Jun 8, 2026
◆Oral PresentationPresentation
Cytokinetics management to participate in Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Jun 3, 2026
◆Oral PresentationPresentation
Cytokinetics management to participate in Jefferies Global Healthcare Conference fireside chat
Jun 1, 2026
▲Product LaunchMYQORZOApprovedPost-Market
First commercial European launch of MYQORZO (aficamten) in Germany
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
May 29, 2026
◆Oral PresentationPresentation
Third Annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB)
May 20, 2026
▲Topline ReadoutAficamtenApprovedClinical Data
Positive topline results in ACACIA-HCM trial
non-obstructive HCMsource ↗
May 19, 2026
◆Oral PresentationPresentation
Cytokinetics management to participate in fireside chat at 2026 RBC Capital Markets Global Healthcare Conference
May 11, 2026
◆Oral PresentationMYQORZOApprovedPresentation
Dose-dependent effects of aficamten compared with metoprolol in obstructive HCM: the MAPLE-HCM study
obstructive hypertrophic cardiomyopathysource ↗
May 11, 2026
▲Full ResultsMYQORZOApprovedClinical Data
Dose-dependent analysis shows MYQORZO outperforms metoprolol across sex and doses
obstructive hypertrophic cardiomyopathysource ↗
May 11, 2026
▲Full ResultsAficamtenApprovedClinical Data
Open-label extension study in Chinese patients shows aficamten well tolerated through 48 weeks
obstructive hypertrophic cardiomyopathysource ↗
May 11, 2026
◆Poster PresentationPresentation
Real-world evidence presentations on HCM burden at ESC Heart Failure 2026
hypertrophic cardiomyopathysource ↗
May 11, 2026
◆Oral PresentationAficamtenApprovedPresentation
Dose-dependent effects of aficamten compared with metoprolol in obstructive HCM: the MAPLE-HCM study
obstructive hypertrophic cardiomyopathysource ↗
Drug Pipeline Intelligence
C57
Pipeline Score $2.4B
Pipeline ValueOvervalued
Valuation Signal12
Drugs Scored0.3x
rNPV / MCap Top 84%
Small Cap (rank 147 of 912)
Percentile RankCytokinetics, Incorporated carries a moderate pipeline score (57/100), with $3.7B risk-adjusted pipeline value, led by omecamtiv mecarbil in Heart Failure (Phase 3), across $65B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| omecamtiv mecarbil Small molecule | Heart Failure | Phase 3 | NCT01380223 | 43% | $2.3B | COMPLETED | 10,705 | - | - | Apr 1, 2006 | MODERATE_RISK | Oct 14, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
aficamten | non-obstructive hypertrophic cardiomyopathy | Phase 3 | 2026-07-07 | positive topline results | Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 Read More | |
aficamten | non-obstructive hypertrophic cardiomyopathy | Phase 3 | 2026-07-07 | positive topline results | Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 Read More | |
aficamten | non-obstructive hypertrophic cardiomyopathy | Phase 3 | 2026-07-07 | positive topline results | Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CYTK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CYTK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CYTKCytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics announced the acceptance of three Late Breaking Science abstracts for presentation at the ESC Congress 2026, highlighting positive results from the ACACIA-HCM trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy. The company will also host an investor event to discuss these findings. The presentations are scheduled for August 28-29, 2026, in Munich, Germany.
Read more →CYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics announced the grant of stock options and restricted stock units to 12 new employees as an inducement for their employment. The awards include performance stock units linked to specific goals. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent while advancing its cardiac treatment pipeline.
Read more →CYTK▼ -5%on this news
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
Cytokinetics has launched its annual Corporate Giving Program, which invites proposals from non-profit organizations aligned with its values. The program will focus on charitable donations aimed at supporting healthcare initiatives, science education, and essential services for local communities, particularly in the San Francisco Bay Area and Greater Philadelphia. Organizations can apply for donations up to $20,000, with the deadline for applications set for August 3, 2026.
Read more →CYTKCytokinetics Launches MYQORZO (aficamten) in European Union, with First Commercial Availability in Germany
Cytokinetics has launched MYQORZO (aficamten) in Germany, marking its first commercial entry into the European market for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This follows the European Commission's approval based on the positive outcomes of the SEQUOIA-HCM Phase 3 trial which demonstrated significant efficacy and safety. The company aims to broaden the availability of MYQORZO across Europe, reinforcing its commitment to patients suffering from this condition.
Read more →CYTKCytokinetics to Participate in June Investor Conferences
Cytokinetics announced its participation in two investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. The company will provide insights into its ongoing research and development efforts, particularly regarding its cardiac myosin inhibitors and activators. Additionally, Cytokinetics plans to present full results from a recent Phase 3 trial at a medical meeting.
Read more →CYTKCytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics, Inc. announced the details of its upcoming Annual Meeting of Stockholders scheduled for May 27, 2026. The meeting will take place at the company's headquarters in South San Francisco, and stockholders of record are entitled to vote or attend. CEO Robert I. Blum will present an overview of the company's performance post-meeting. Cytokinetics is advancing multiple investigational medicines in cardiac muscle dysfunction, including MYQORZO® and omecamtiv mecarbil.
Read more →CYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics, Inc. announced the grant of stock options and restricted stock units to eight employees as inducements under Nasdaq Listing Rule 5635(c)(4). These grants, amounting to 20,807 stock options and 13,793 RSUs, are designed to support the company's growth and attract talent. The RSUs will vest over three years while the stock options have a 10-year term. Cytokinetics continues to advance its pipeline, including the recently successful Phase 3 trial of aficamten for treating non-obstructive hypertrophic cardiomyopathy.
Read more →CYTKCytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)
Cytokinetics will host its third annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on May 29, 2026, in San Francisco. The symposium aims to foster collaboration and dialogue among researchers in muscle biology, featuring presentations from distinguished speakers on topics such as cardiac and skeletal muscle biology. Registration for the event is free, although space is limited. Cytokinetics continues to emphasize its commitment to advancing research and innovation in muscle-related diseases and treatments.
Read more →CYTKCytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Cytokinetics will participate in the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The management team will engage in a fireside chat, which can be accessed via a live webcast. The company is advancing its pipeline, including the recently successful Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy.
Read more →CYTKCytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
Cytokinetics presented new data on MYQORZO (aficamten) at the ESC Heart Failure 2026 Congress, highlighting its effectiveness in treating obstructive hypertrophic cardiomyopathy (oHCM). The data from multiple Phase 3 trials demonstrated significant improvements in exercise capacity and safety profiles compared to traditional beta-blockers. Long-term studies showed no increase in arrhythmias, reinforcing MYQORZO's clinical benefits across diverse patient groups.
Read more →CYTKCytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
Cytokinetics has successfully closed a public offering of 11,338,028 shares of common stock, generating gross proceeds of approximately $805 million. The offering included the full exercise of the underwriters' option to purchase additional shares. Major financial institutions managed the offering, and the securities were offered under a shelf registration statement with the SEC.
Read more →CYTKCytokinetics Announces Pricing of Upsized Public Offering of Common Stock
Cytokinetics has announced the pricing of an upsized public offering of 9,859,155 shares at $71.00 per share, aiming to raise around $700 million. The offering is set to close on May 8, 2026, pending customary conditions. The company has also granted underwriters a 30-day option for additional shares. This move supports Cytokinetics' ongoing development of cardiovascular therapies.
Read more →CYTKCytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
Cytokinetics reported strong first quarter 2026 results, highlighting the successful U.S. launch of MYQORZO, which saw over 680 patients treated. The ACACIA-HCM trial achieved its primary endpoints, with full results to be presented at an upcoming medical congress. The company also noted its financial stability with significant cash reserves and upcoming regulatory milestones.
Read more →CYTK▲ +16.7%on this newsshared move
Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update
Cytokinetics has made forward-looking statements regarding its research and development activities, including clinical trials and regulatory processes. The company asserts that actual results may vary from these statements due to numerous risks and uncertainties in drug development and commercialization. Notably, Cytokinetics has FDA approval for its drug MYQORZO designed to improve functional capacity and symptoms for patients with obstructive hypertrophic cardiomyopathy (oHCM). The company’s financial position appears strong, with access to capital for future growth and expansion.
Read more →CYTK▲ +16.7%on this newsshared move
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy (HCM). The trial met its dual primary endpoints, demonstrating significant improvements in the Kansas City Cardiomyopathy Questionnaire (KCCQ) and maximal exercise performance. The findings suggest that aficamten may provide meaningful benefits for patients with a condition that currently has no approved therapies. The company plans to discuss results with the U.S. FDA and regulatory authorities in the future.
Read more →CYTK▲ +16.7%on this newsshared move
Cytokinetics Announces Proposed Public Offering of Common Stock
Cytokinetics has announced a proposed public offering of approximately $650 million in common stock, subject to market conditions. The offering will be managed by major financial institutions, including Morgan Stanley and Goldman Sachs. While the company has a promising pipeline of cardiovascular treatments, there are uncertainties regarding the offering's completion and terms.
Read more →CYTKCytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
Cytokinetics, Inc. is set to announce topline results from the pivotal Phase 3 ACACIA-HCM clinical trial, evaluating Aficamten in patients with non-obstructive hypertrophic cardiomyopathy, on May 5, 2026. A conference call will follow at 8:00 AM Eastern Time to discuss the outcome. The company is recognized for its focus on advancing therapies for cardiac muscle dysfunction, with additional treatments in development for related conditions. This announcement marks a key milestone for the company as they continue to innovate in cardiovascular medicine.
Read more →CYTKCytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
Cytokinetics has announced nine upcoming presentations at the European Society of Cardiology Heart Failure 2026 Congress in Barcelona. The presentations will focus on MYQORZO (aficamten), which has recently been approved for treating symptomatic obstructive hypertrophic cardiomyopathy. Notably, a late-breaking oral presentation will compare aficamten's effects with metoprolol in obstructive HCM patients.
Read more →CYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - April 20, 2026
Cytokinetics announced the grant of stock options and restricted stock units to 33 new employees as an inducement for their employment. The RSUs will vest over three years, while the stock options will vest over four years with a 10-year term. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent.
Read more →CYTKCytokinetics to Announce First Quarter Results on May 5, 2026
Cytokinetics, a biopharmaceutical company specializing in cardiovascular treatments, announced its plan to release first quarter results on May 5, 2026. Following the results, a conference call will be held to discuss the financial outcomes and provide updates on their business efforts. The company has a noteworthy pipeline including MYQORZO, recently approved for use, as well as investigational therapies targeting various heart conditions. Future performance remains uncertain as they navigate risks associated with research and development activities.
Read more →CYTKCytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Cytokinetics, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The management team will engage in a fireside chat, which can be accessed via a live webcast. Cytokinetics is known for its advancements in cardiovascular biopharmaceuticals, particularly with its approved drug MYQORZO® and investigational therapies.
Read more →CYTKCytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
Cytokinetics, Inc. announced four scientific presentations on MYQORZO (aficamten) at the upcoming American College of Cardiology Annual Scientific Session. These presentations include new analyses that reinforce prior data showing aficamten's efficacy in improving exercise capacity for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients. MYQORZO, recently approved for this indication, has a safety profile consistent with previous findings. The company aims to provide further evidence to assist in clinical decision-making for physicians and patients.
Read more →CYTKCytokinetics to Participate in March 2026 Investor Conferences
Cytokinetics, Inc. announced its participation in several investor conferences in March 2026. The management team will engage with interested parties through live webcasts, which will be archived for 90 days. The company continues to advance its pipeline, including approved and investigational therapies for cardiac muscle dysfunction.
Read more →CYTKCytokinetics to Participate in March Investor Conferences
Cytokinetics, Inc. has announced its participation in several investor conferences throughout March 2026. The management team will engage in fireside chats and one-on-one meetings at prominent events, including the Leerink and Barclays Global Healthcare Conferences in Miami Beach, FL. The company continues to focus on developing its pipeline of cardiac treatments, including approved drugs and investigational therapies for various heart conditions.
Read more →CYTK▼ -10.3%on this newsshared move
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
Cytokinetics reported its fourth quarter and full year 2025 financial results, highlighting the FDA approval of MYQORZO for obstructive HCM. The company is launching MYQORZO in the U.S. and plans a European launch in Germany. Financial guidance for 2026 indicates a strong cash position, supporting ongoing clinical trials and potential label expansions.
Read more →CYTKCytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has received European Commission approval for MYQORZO® (aficamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. The approval is based on positive results from the SEQUOIA-HCM Phase 3 trial, which showed significant improvements in exercise capacity. MYQORZO is set to launch in Germany in Q2 2026, providing new treatment options for patients.
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on February 24, 2026
Cytokinetics, Inc. announced its schedule to report fourth quarter results on February 24, 2026, followed by a conference call to discuss the outcomes. The company continues to advance its portfolio, including its cardiac myosin inhibitor MYQORZO™, which is approved for treating hypertrophic cardiomyopathy and is under review in Europe. Additionally, Cytokinetics is developing other investigational drugs for various heart conditions, underscoring its commitment to cardiovascular health.
Read more →CYTKCytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
Cytokinetics has awarded grants to two patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM). These grants will enable the organizations to enhance community engagement and awareness through various communication initiatives. The supported projects include a video series and a digital campaign aimed at educating families about HCM.
Read more →CYTKCytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
Cytokinetics has launched the 'On Track with HCM' campaign featuring Olympic gold medalist Sydney McLaughlin-Levrone and her father, Willie McLaughlin, who suffered from hypertrophic cardiomyopathy (HCM). The campaign aims to raise awareness about HCM and provide practical insights for patients managing the disease. It includes a website and videos sharing personal experiences and expert advice.
Read more →CYTKCytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
Cytokinetics has announced the availability of MYQORZO (aficamten) in the U.S. for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This cardiac myosin inhibitor aims to improve functional capacity and symptoms. The FDA approved MYQORZO based on positive Phase 3 trial results, although it carries a risk of heart failure and is subject to a REMS program.
Read more →CYTKCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 20, 2026
Cytokinetics announced the grant of stock options and restricted stock units to eight new employees as an inducement for their employment. The RSUs will vest over three years, while stock options will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to its workforce.
Read more →CYTK▲ +5.5%on this news
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Cytokinetics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Robert I. Blum will lead the presentation, which can be accessed via a live webcast. The company is known for its advancements in treatments for cardiac muscle dysfunction, including the recently approved MYQORZO™.
Read more →CYTKCytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
Cytokinetics has received FDA approval for MYQORZO (aficamten), a treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This approval is based on positive results from the SEQUOIA-HCM clinical trial, which demonstrated significant improvements in exercise capacity and symptom relief. MYQORZO will be available in the U.S. starting January 2026, accompanied by a patient support program.
Read more →CYTKCytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has received approval from the NMPA for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy in China. This approval activates a $7.5 million milestone payment from Sanofi, which holds exclusive rights for commercialization in Greater China. The drug is also under review in the U.S. and has received a positive opinion from the EMA for EU marketing authorization.
Read more →CYTKCytokinetics Announces Positive CHMP Opinion of MYQORZO (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has received a positive opinion from the CHMP for MYQORZO (aficamten) for treating obstructive hypertrophic cardiomyopathy (oHCM). A final decision from the European Commission is expected in Q1 2026. The recommendation is based on successful clinical trial results that indicated significant improvements in exercise capacity and safety. The company is accelerating its readiness for potential EU marketing to provide new treatment options to patients in need.
Read more →CYTKCytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – CYTK
Cytokinetics, Incorporated is facing a class action lawsuit for violations of securities laws. The lawsuit claims that the company made false and misleading statements regarding the expected FDA approval of aficamten and failed to submit a necessary Risk Evaluation and Mitigation Strategy, potentially jeopardizing the approval process. Shareholders are encouraged to participate in the lawsuit to recover losses incurred during the class period. The deadline for joining the case is November 17, 2025.
Read more →CYTKCytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy
Cytokinetics, Inc. has pledged support to a three-year initiative led by the American Heart Association aimed at improving care for individuals with hypertrophic cardiomyopathy (HCM). This initiative is designed to address existing disparities in access to care and timely diagnoses. Cytokinetics will contribute to enhancing healthcare delivery by increasing participation in a national HCM Registry and offering patient support services. The company’s involvement underscores a commitment to advancing systematic improvements in heart health care for HCM patients across the U.S.
Read more →CYTKCytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK
ClaimsFiler has alerted investors in Cytokinetics, Incorporated (CYTK) that they must file lead plaintiff applications by November 17, 2025, regarding a class action lawsuit. This lawsuit is based on claims that Cytokinetics and certain executives failed to disclose crucial information during the defined Class Period. The firm disclosed that the FDA opted not to convene a meeting to review their aficamten drug application, which contributed to a notable drop in stock price. The case is being pursued in the Northern District of California.
Read more →CYTKCytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
Kahn Swick & Foti, LLC has issued a reminder to investors in Cytokinetics, Incorporated about the upcoming deadline to file lead plaintiff applications in a class action lawsuit. The lawsuit alleges that Cytokinetics and its executives failed to disclose key information violating federal securities laws. Notably, the company faced a drop in share price after the FDA declined to hold an advisory committee meeting regarding its New Drug Application for aficamten. Interested investors have until November 17, 2025, to act.
Read more →CYTKCytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
Cytokinetics presented additional data from the MAPLE-HCM study at major scientific sessions, highlighting aficamten's superior efficacy over metoprolol in improving exercise capacity and patient-reported outcomes. The study demonstrated significant clinical response rates and improvements in cardiac biomarkers. However, the rate of adverse events was similar between both treatments.
Read more →CYTKCytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK
Cytokinetics, Incorporated is currently the subject of a class action securities lawsuit filed by Levi & Korsinsky, LLP. The lawsuit alleges that the company made misleading statements about the New Drug Application (NDA) process for its drug aficamten, leading to inflated stock prices and subsequent losses for investors. Specifically, the suit claims the company failed to disclose material risks associated with a Risk Evaluation and Mitigation Strategy (REMS). As a result, investors are urged to consider their legal rights and may be entitled to compensation without incurring costs.
Read more →CYTKCytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update
Cytokinetics reported its Q3 2025 financial results, highlighting progress towards the PDUFA date for Aficamten set for December 26, 2025. The company is preparing for a commercial launch while maintaining a strong financial position with approximately $1.25 billion in cash. Recent trial results further support Aficamten's efficacy in treating obstructive hypertrophic cardiomyopathy.
Read more →CYTKCytokinetics, Incorporated Sued for Securities Law Violations - Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights – CYTK
Cytokinetics, Incorporated is being sued for securities law violations, specifically regarding allegations of false statements made about the regulatory timeline for aficamten's New Drug Application (NDA). The lawsuit claims that the company misled investors about expected FDA approval and failed to disclose the submission of a required Risk Evaluation and Mitigation Strategy (REMS), which puts the approval process at risk. As a result, shareholders who purchased stock during the affected period suffered significant financial losses. Shareholders are encouraged to register with The Gross Law Firm by November 17, 2025, to discuss their rights and potential participation in the lawsuit.
Read more →CYTKCytokinetics to Participate in November Investor Conferences
Cytokinetics announced its participation in several investor conferences in November. The management team will engage in discussions accessible via live webcasts. The company is also preparing for potential regulatory approvals for aficamten, a cardiac myosin inhibitor, following successful trial results. Cytokinetics continues to develop additional therapies for cardiac muscle dysfunction.
Read more →CYTK▼ -5.6%on this newsshared move
CYTOKINETICS CLASS ACTION: Bragar Eagel & Squire, P.C. Urges Cytokinetics Stockholders to Contact the Firm Regarding Their Rights Before November 17th
A class action lawsuit has been filed against Cytokinetics in the Northern District of California on behalf of investors who acquired stock between December 27, 2023, and May 6, 2025. The lawsuit claims that the company made false and misleading statements about the timeline for the FDA approval of aficamten, leading to significant losses for investors. The complaint highlights the company's failure to include a necessary Risk Evaluation and Mitigation Strategy in the NDA submission, which may have contributed to delays in the regulatory process. Plaintiffs have until November 17, 2025, to apply as lead plaintiffs in the case.
Read more →CYTKCytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
Cytokinetics has announced upcoming presentations at the Hypertrophic Cardiomyopathy Medical Society and American Heart Association Scientific Sessions 2025. The presentations will focus on the investigational drug Aficamten and its effects on patients with obstructive hypertrophic cardiomyopathy. Notable presentations include Late Breaking Science sessions and oral presentations highlighting the drug's impact on health status and patient-reported outcomes.
Read more →CYTKCytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights – CYTK
Cytokinetics, Incorporated is currently subject to a securities fraud class action lawsuit alleging that it made false and misleading statements regarding the New Drug Application for aficamten. The firm allegedly misrepresented expected FDA approval timelines and failed to disclose critical risks related to the Risk Evaluation and Mitigation Strategy. This has led to claims that shareholders suffered losses after learning the true circumstances surrounding the regulatory process. Shareholders are encouraged to register for potential recovery before the deadline on November 17, 2025.
Read more →CYTKCYTOKINETICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds CYTK Investors to Contact the Firm Before November 17th
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Cytokinetics for allegedly making false claims about the NDA submission for aficamten, which could mislead investors. The lawsuit involves investors who purchased shares between December 27, 2023, and May 6, 2025, with a deadline of November 17, 2025, to apply as lead plaintiffs. The allegations include failing to disclose critical risks related to regulatory submissions that caused stock prices to be artificially inflated. This revelation resulted in significant financial losses for affected investors when the misleading information came to light.
Read more →CYTKCYTOKINETICS CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Cytokinetics Investors of the Filed Class Action Lawsuit and Urges Investors to Contact the Firm Before November 17th
Cytokinetics is facing a class action lawsuit for allegedly making false statements regarding the NDA submission timeline for aficamten. The lawsuit claims the company misled investors by not disclosing critical risks related to its regulatory process. A significant revelation during an earnings call indicated that Cytokinetics submitted its NDA without an essential Risk Evaluation and Mitigation Strategy, leading to inflated stock prices and subsequent losses for investors. Those affected from the Class Period have until November 17, 2025, to join the lawsuit.
Read more →CYTK▲ +5%on this newsshared move
Cytokinetics to Announce Third Quarter Results on November 5, 2025
Cytokinetics, Inc. will announce its third quarter results on November 5, 2025, at 4:00 PM ET. Following the announcement, a conference call will be held at 4:30 PM ET to discuss the financial results and business updates. The call will be webcast and available for replay on the company's website.
Read more →CYTKCYTOKINETICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Cytokinetics, Incorporated due to alleged misleading statements regarding the New Drug Application for aficamten. The lawsuit claims the company misrepresented the timeline for FDA approval and omitted important risks related to a required Risk Evaluation and Mitigation Strategy. Investors who purchased stock during the specified period experienced losses when these truths were disclosed. Individuals who believe they may qualify for the action are encouraged to contact the law firm handling the case.
Read more →CYTKCYTOKINETICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK
ClaimsFiler has informed Cytokinetics investors that they must file for lead plaintiff status by November 17, 2025, in a securities class action lawsuit. The lawsuit claims Cytokinetics failed to disclose critical information during the class period, violating federal securities laws. Following adverse announcements regarding its New Drug Application for aficamten, the company's share price dropped significantly. The case is being handled in the U.S. District Court for the Northern District of California.
Read more →CYTKCYTOKINETICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
A class action lawsuit has been filed against Cytokinetics, reminding investors to apply as lead plaintiffs by November 17, 2025. The lawsuit claims that the company and certain executives failed to disclose critical information during the class period, leading to violations of federal securities laws. Notably, the FDA did not convene a meeting regarding the company's NDA for aficamten, which was submitted without a Risk Evaluation and Mitigation Strategy. Due to these disclosures, Cytokinetics' stock price has experienced a noticeable decline.
Read more →CYTK▲ +6.9%on this newsshared move
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
Cytokinetics presented new data on Aficamten at the HFSA Annual Scientific Meeting 2025, highlighting its effectiveness in improving exercise capacity in patients with hypertrophic cardiomyopathy (HCM). The MAPLE-HCM trial showed Aficamten outperformed Metoprolol in various exercise performance metrics. Additionally, long-term data from the FOREST-HCM trial indicated sustained benefits and tolerability in patients with non-obstructive HCM.
Read more →CYTK▲ +6.9%on this newsshared move
Cytokinetics, Incorporated Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – CYTK
Cytokinetics, Incorporated is facing a class action lawsuit for securities law violations. The lawsuit claims that the company misled investors about the timeline for the New Drug Application (NDA) approval of aficamten. Specifically, it was alleged that Cytokinetics did not disclose important risks regarding the missing Risk Evaluation and Mitigation Strategy (REMS) that could affect the approval process. As a result, shareholders experienced losses after the company's misleading statements were uncovered during an earnings call.
Read more →CYTKCytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
Cytokinetics has announced its eighth annual Communications Grant Program, aimed at supporting patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure. The program will award five grants to enhance communications and outreach efforts. Applications are due by November 3, 2025, with recipients announced in January 2026.
Read more →CYTKCytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
Cytokinetics, Inc. will present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025. The presentation will highlight the company's advancements in cardiac therapies, including the promising results from the SEQUOIA-HCM trial for aficamten. Interested parties can access the live webcast through the Cytokinetics website.
Read more →CYTKCYTOKINETICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated and Encourages Investors to Contact the Firm
Cytokinetics, Inc. is facing a class action lawsuit filed by Bragar Eagel & Squire, alleging that the company made materially false statements regarding the timeline for the New Drug Application for aficamten. The lawsuit claims that Cytokinetics misled investors about the FDA submission process and failed to disclose critical information regarding the Risk Evaluation and Mitigation Strategy (REMS). As a result, investors experienced substantial losses when the true state of the company's regulatory situation became known. The legal action seeks to protect the rights of stockholders who purchased shares within a specified timeframe.
Read more →CYTKCytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
Cytokinetics, Incorporated announced three presentations at the Heart Failure Society of America Annual Scientific Meeting 2025, including two Late Breaking Clinical Research sessions. Researchers will present findings on Aficamten, an investigational drug for patients with non-obstructive hypertrophic cardiomyopathy (HCM), highlighting its safety and efficacy over 96 weeks and its impact on exercise performance. The meeting will take place in Minneapolis from September 26 to 29, 2025, showcasing advancements in heart failure treatments. Aficamten is under regulatory review in multiple regions, including the U.S. and Europe.
Read more →CYTKCytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
Cytokinetics has announced the pricing of an upsized offering of $650 million in convertible senior notes due in 2031. This offering, initially set at $550 million, serves primarily to refinance existing notes due in 2027, extending their maturity and reducing the coupon rate from 3.50% to 1.75%. The proceeds are designated to support various corporate purposes, including the anticipated commercial launch of their drug aficamten, which has shown positive results in clinical trials for treating obstructive hypertrophic cardiomyopathy.
Read more →CYTKCytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes 2025-09-16
Cytokinetics announced its intention to privately place $550 million in convertible senior notes due 2031. The funds will support the launch of aficamten and further develop its research pipeline. Additionally, a portion of the proceeds will be used for potential note exchange transactions involving its existing 2027 notes. The offering reflects Cytokinetics' strategy to bolster its financial resources as it aims for regulatory approvals in the cardiovascular space.
Read more →CYTKCytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
Cytokinetics announced its plan to offer $550 million in convertible senior notes due 2031 in a private placement aimed at qualified institutional buyers. The financing is intended to support the potential commercial launch and further development of aficamten, along with other general corporate purposes. Noteholders will have the option to convert their notes under certain conditions, but the offering's success is contingent on market conditions and other factors. The company currently navigates uncertainties related to the exchange terms for existing convertible senior notes due 2027.
Read more →CYTK▲ +40.4%on this news
CYTOKINETICS PRESENTS NEW DATA RELATED TO AFICAMTEN AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simul
Cytokinetics presented new data on aficamten at the European Society of Cardiology Congress 2025, highlighting its superiority in improving cardiac structure and function compared to metoprolol in the MAPLE-HCM study. The annual incidence of atrial fibrillation was found to be 1.5%, which is consistent with predicted rates for patients with hypertrophic cardiomyopathy. Additional analyses reinforced aficamten's long-term safety and clinical benefits, as well as the low occurrence of adverse events. The FDA is currently reviewing aficamten, with a target action date set for December 26, 2025.
Read more →CYTK▲ +40.4%on this news
CYTOKINETICS ANNOUNCES PRIMARY RESULTS FROM MAPLE-HCM PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Positive Trial Demonstrates Superiority of Aficamte
Cytokinetics announced positive primary results from its Phase 3 MAPLE-HCM trial, showing aficamten's superiority over the standard beta-blocker metoprolol in improving exercise capacity for patients with symptomatic obstructive hypertrophic cardiomyopathy. Presenting at the European Society of Cardiology Congress 2025, the trial included 175 patients and revealed statistically significant improvements in key endpoints. The results suggest aficamten may alter the treatment landscape for obstructive HCM, which has historically relied on beta-blockers. The drug is currently under FDA review, with a target action date set for December 26, 2025.
Read more →CYTK▲ +40.4%on this newsshared move
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
Cytokinetics presented new data on aficamten at the European Society of Cardiology Congress 2025, highlighting its effectiveness in improving cardiac structure and function compared to metoprolol. New analyses from the MAPLE-HCM study indicated a low annual incidence rate of atrial fibrillation, consistent with expected rates in hypertrophic cardiomyopathy patients. The long-term safety profile of aficamten remains stable, further strengthening its clinical evidence. Cytokinetics plans to host an investor event to discuss these findings in detail.
Read more →CYTK▲ +40.4%on this newsshared move
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Cytokinetics reported positive primary results from its MAPLE-HCM trial, showcasing aficamten's superiority over metoprolol in improving exercise capacity for patients with obstructive hypertrophic cardiomyopathy. Aficamten not only excelled on primary endpoints but also outperformed metoprolol in five of six secondary measures. The trial, which featured 175 participants, indicated significant enhancements in patient symptoms and functional class, suggesting a potential paradigm shift in treatment protocols. Results were presented at the European Society of Cardiology Congress and published in The New England Journal of Medicine.
Read more →CYTKCytokinetics to Participate in September Investor Conferences
Cytokinetics has announced its participation in several investor conferences throughout September 2025, including events hosted by Citi, Wells Fargo, Cantor, and Morgan Stanley. The company is focusing on its innovative pipeline, particularly aficamten, a cardiac myosin inhibitor with positive Phase 3 trial results. Additionally, Cytokinetics is developing other cardiac therapies aiming to address various forms of heart failure and muscular dystrophy. Webcast access to the discussions will be available on their website, which will also archive the sessions for 90 days after the events.
Read more →CYTKCytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
Cytokinetics has revealed plans for five presentations concerning aficamten at the European Society of Cardiology Congress 2025 in Madrid, Spain. Notable presentations include results from the MAPLE-HCM trial, which compares aficamten to metoprolol in treating obstructive hypertrophic cardiomyopathy (HCM). The company will also host an investor event to discuss these findings and further developments relating to aficamten and other drug candidates. This reflects Cytokinetics' ongoing commitment to advancing treatments for cardiac muscle dysfunction.
Read more →CYTKCytokinetics Names Jim Daly to Board of Directors
Cytokinetics has appointed James M. Daly to its Board of Directors, effective August 19, 2025. Daly brings extensive experience in biopharmaceuticals, particularly in commercialization, having previously served as Chief Commercial Officer at Incyte Corporation. His background includes leadership roles at Amgen, where he launched several successful medicines. Cytokinetics is preparing for potential regulatory approval and commercialization of aficamten, a cardiac myosin inhibitor, following positive clinical trial results.
Read more →CYTKCYTOKINETICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled
Cytokinetics (CYTK) provided a comprehensive update on its second quarter financial results and business developments for 2025. The company is making significant strides in the regulatory reviews of its lead product, Aficamten, for obstructive hypertrophic cardiomyopathy (HCM) across multiple regions, with a late-cycle meeting scheduled with the FDA. Financially, the company reported a net loss, yet retains a healthy cash reserve to support its commercialization plans and ongoing research initiatives.
Read more →CYTKCytokinetics to Announce Second Quarter Results On August 7, 2025
Cytokinetics, Incorporated has announced that it will report its second quarter results on August 7, 2025. Following the results, a conference call will be held to discuss the financial outcomes and provide business updates. The company is making strides in the development of aficamten, a cardiac myosin inhibitor, which is nearing potential regulatory approval after a successful Phase 3 trial. Additionally, Cytokinetics is advancing several other cardiac and muscle therapies.
Read more →CYTKCytokinetics Announces Call For Proposals For Annual Corporate Giving Program
Cytokinetics, Incorporated (CYTK) has announced the launch of its annual Corporate Giving Program, aimed at providing donations to eligible non-profit organizations. This initiative is focused on supporting equitable healthcare initiatives, particularly in cardiovascular disease and diversity in science education. The program is set to offer donations of up to $20,000 to qualified organizations that are not engaged in the practice of healthcare. Applications for the program are open until August 4, 2025, signaling the company's commitment to social responsibility and community support.
Read more →CYTKCytokinetics to Participate in the Jefferies Global Healthcare Conference
Cytokinetics announced its participation in the Jefferies Global Healthcare Conference scheduled for June 4, 2025. The event will feature a fireside chat with the company's management team, allowing for broader engagement with investors. This participation is part of Cytokinetics' efforts to showcase its advancements in developing treatments for cardiac muscle dysfunction, including the promising drug aficamten, which has shown positive trial results. The company continues to explore additional therapeutic options in its pipeline.
Read more →CYTKCytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
Cytokinetics presented new analyses related to aficamten at the European Society of Cardiology Heart Failure 2025 Congress. The findings from the SEQUOIA-HCM trial indicate that aficamten effectively improves exercise capacity and symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), regardless of baseline symptom severity. Additionally, significant disparities in cardiovascular outcomes were identified among females and older patients with non-obstructive HCM. Aficamten continues to undergo regulatory review as a potential treatment for these conditions.
Read more →CYTKCytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology
Cytokinetics announced the second annual Contemporary Landscapes in Muscle Biology Research Symposium, set to take place on May 30, 2025, in San Francisco. The event aims to promote collaboration and dialogue among researchers in the field of muscle biology, featuring notable speakers and presentations on innovations in cardiac and skeletal muscle biology. The company is also preparing for the regulatory approval of aficamten, following positive trial results, alongside its ongoing development of various other cardiac therapeutic agents.
Read more →CYTKCytokinetics Announces Positive Topline Results From MAPLE-HCM
Cytokinetics, Incorporated announced positive topline results from the MAPLE-HCM Phase 3 trial, showing that aficamten significantly improved peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy compared to the standard beta blocker metoprolol. The trial met its primary endpoint, indicating aficamten's favorable safety profile as well. The results suggest potential for aficamten as an effective monotherapy in this patient population. Full results will be presented at an upcoming medical conference.
Read more →CYTKCytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress
Cytokinetics has announced its participation in the Heart Failure 2025 Congress, where it will present three Late Breaking Science presentations and one ePoster. The presentations will focus on critical developments related to aficamten and omecamtiv mecarbil, which are being evaluated for their efficacy in treating various forms of heart failure. This event marks a key moment for Cytokinetics as it prepares for potential regulatory approvals and commercialization of its drug candidates targeting cardiac muscle dysfunction.
Read more →CYTK▼ -7.4%on this newsshared move
CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to
Cytokinetics reported its financial results for Q1 2025, including significant updates on its lead candidate, aficamten, for obstructive HCM. The FDA has extended the PDUFA date to December 26, 2025, due to a request for a Risk Evaluation and Mitigation Strategy (REMS). The company reported a strong financial position with over $1.1 billion in cash and completed enrollment in pivotal trials ACACIA-HCM and MAPLE-HCM, with topline results expected soon. Cytokinetics continues to advance its clinical programs while preparing for commercial readiness for aficamten.
Read more →CYTKCytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced that the FDA has extended the PDUFA action date for aficamten, its drug for obstructive hypertrophic cardiomyopathy, to December 26, 2025. This extension is due to the FDA needing more time to review the proposed Risk Evaluation and Mitigation Strategy submitted by Cytokinetics. The company remains optimistic about the drug's benefit-risk profile, especially following positive results from the SEQUOIA-HCM trial. Importantly, no additional studies have been requested, suggesting the FDA may be satisfied with the existing clinical data.
Read more →CYTKCytokinetics to Participate in May Investor Conferences
Cytokinetics announced its participation in two investor conferences in May 2025, highlighting its commitment to engaging with stakeholders. The events will include fireside chats at the Citizens Life Sciences Conference and the RBC Capital Markets Global Healthcare Conference, both taking place in New York City. The company is advancing its cardiac myosin inhibitor, aficamten, and preparing for regulatory approval following successful clinical trials for obstructive hypertrophic cardiomyopathy. Additionally, Cytokinetics is developing other innovative therapies for cardiovascular diseases.
Read more →CYTKCytokinetics to Announce First Quarter Results on May 6, 2025
Cytokinetics, Incorporated (Nasdaq: CYTK) announced it will report its first quarter results on May 6, 2025, with a subsequent conference call to discuss the findings. The company is focused on creating a muscle biology franchise, with significant advancements towards regulatory approvals for aficamten, a cardiac myosin inhibitor. Additionally, Cytokinetics is developing other treatments for heart failure and muscular dystrophy, showcasing a strong commitment to addressing muscle dysfunction diseases.
Read more →CYTK▼ -6.9%on this news
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Cytokinetics, Inc. will participate in the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025. The management team's presentation will be accessible through a live webcast on the company's website. The company is focusing on the commercialization of aficamten, following positive clinical trial results, and is also developing additional therapies for cardiac and muscle-related conditions. Forward-looking statements regarding these developments are made with caution due to inherent risks and uncertainties in the biotechnology industry.
Read more →CYTKCytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community
Cytokinetics has launched EARTH-HCM, a unique public health education tool that utilizes real-world data to address the challenges faced by hypertrophic cardiomyopathy (HCM) patients. This interactive online platform aims to visualize and analyze population disparities in treatment and outcomes for individuals with HCM in the U.S. It has been developed in collaboration with various leading academic institutions and seeks to enhance awareness and education on HCM while promoting equitable access to care. The tool will be frequently updated with new data to improve its insights and efficacy.
Read more →CYTKCytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo
Cytokinetics, Incorporated announced five presentations at the American College of Cardiology Annual Scientific Session & Expo focusing on aficamten, an investigational cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM). Key data includes analyses on the drug's metabolism, safety in combination with disopyramide, and its long-term effects on cardiac structure and function. The findings suggest significant improvements in patients with obstructive HCM, aiming to enhance clinical practice for this condition.
Read more →CYTKCYTOKINETICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China
Cytokinetics, Incorporated reported significant advancements in its Q4 2024 financial results and business strategy, including preparations for the commercial launch of aficamten, a cardiac myosin inhibitor. With regulatory submissions underway in the U.S., Europe, and China, and a targeted PDUFA date set for September 26, 2025, the company is optimistic about its future prospects. Cytokinetics holds a strong cash position of around $1.2 billion, supporting its ongoing clinical trials and strategic partnerships aimed at improving patient access to novel treatments.
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on February 27, 2025
Cytokinetics, Incorporated is set to announce its fourth quarter results on February 27, 2025. A conference call will follow the results announcement to discuss operational and financial insights. The company is actively working on several drug candidates, including aficamten and omecamtiv mecarbil, aimed at improving muscle performance in patients with heart disease and other muscle-related conditions. Positive outcomes from clinical trials suggest a promising future for these treatments.
Read more →CYTKCytokinetics Names Robert E. Landry to Board of Directors
Cytokinetics has announced the appointment of Robert E. Landry to its Board of Directors, bringing significant financial and operational expertise from his tenure at Regeneron Pharmaceuticals. This appointment comes as Cytokinetics prepares for the potential commercialization of its first medicine, aficamten, following positive Phase 3 trial results. Mr. Landry will leverage his extensive background in finance and operational leadership to help guide the company's growth as it aims for regulatory approvals and expanding its innovative treatments for muscle-related conditions.
Read more →CYTKCytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Cytokinetics, Inc. is scheduled to participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025. CEO Robert I. Blum will engage in a virtual fireside chat that will be accessible via the company's website. Cytokinetics specializes in muscle biology and is preparing for potential regulatory approvals for aficamten, a treatment for obstructive hypertrophic cardiomyopathy, following positive clinical trial results. The company is also advancing other cardiac treatments, highlighting its commitment to innovative medical solutions.
Read more →CYTKCytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program
Cytokinetics has announced the recipients of its 2025 Communications Grant Program, awarding a total of $100,000 to five patient advocacy organizations dedicated to hypertrophic cardiomyopathy (HCM) and heart failure. Each organization will receive $20,000 to support initiatives that expand awareness and community engagement. The grants will enable recipients to launch educational projects, enhancing resources and outreach for patient support. This reflects Cytokinetics' ongoing commitment to advancing cardiovascular health education and patient advocacy.
Read more →CYTKCytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
Cytokinetics has commenced the AMBER-HFpEF trial, a Phase 2 clinical study evaluating CK-586 in patients with heart failure with preserved ejection fraction (HFpEF). This trial is designed to assess the safety, tolerability, and pharmacokinetics of CK-586. Approximately 60 patients will participate, receiving either CK-586 or a placebo over a 12-week period. The study aims to address a subgroup of HFpEF patients who currently have limited treatment options and poor prognosis.
Read more →CYTKCytokinetics Announces 2025 Corporate Milestones and Vision 2030
Cytokinetics, Inc. has announced its corporate milestones for 2025 and its long-term Vision 2030 strategy. The key focus for 2025 is the anticipated approval and commercial launch of aficamten for obstructive hypertrophic cardiomyopathy (HCM). The company is also advancing its clinical trials for aficamten and other cardiac therapies while pursuing global market access. Cytokinetics aims to establish itself as a leader in muscle biology biopharma with ambitious expansion plans over the next five years.
Read more →CYTKCytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cytokinetics, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The presentation will be led by CEO Robert I. Blum and will focus on the company's advancements in muscle biology-directed drug candidates for cardiovascular diseases. Aficamten, a cardiac myosin inhibitor, has shown positive Phase 3 trial results in patients with hypertrophic cardiomyopathy, and the company is preparing for its potential commercialization. Cytokinetics is also developing other promising treatments for heart failure and muscular dystrophies.
Read more →CYTKCytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced that the European Medicines Agency has validated the Marketing Authorization Application for aficamten, aimed at treating obstructive hypertrophic cardiomyopathy (HCM). This follows similar regulatory processes in the U.S. and China. The application is underpinned by results from the SEQUOIA-HCM Phase 3 clinical trial, which demonstrated significant improvements in exercise capacity and other cardiac measures. Aficamten is poised for further review, with the potential for commercialization if approved.
Read more →CYTKCytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Cytokinetics announced that Sanofi has acquired exclusive rights to develop and commercialize aficamten for hypertrophic cardiomyopathy in Greater China. This agreement follows aficamten's Breakthrough Therapy Designation for obstructive HCM in China. Cytokinetics will receive up to $150 million in milestone payments and royalties on future sales. The collaboration aims to leverage Sanofi's cardiovascular expertise to improve treatment accessibility for patients with HCM in the region.
Read more →CYTKCytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
Cytokinetics has announced the commencement of COMET-HF, a Phase 3 clinical trial aimed at evaluating omecamtiv mecarbil for patients suffering from symptomatic heart failure with severely reduced ejection fraction. The trial, launched in partnership with Duke Clinical Research Institute, seeks to address a significant unmet medical need in this patient cohort. Omecamtiv mecarbil is a cardiac myosin activator that aims to improve heart contractility and has shown promising results in earlier studies. The trial will involve approximately 1,800 patients and focus on their cardiovascular outcomes over time.
Read more →CYTKCytokinetics to Participate in December Investor Conferences
Cytokinetics, Incorporated (CYTK) is set to participate in two investor conferences in December 2024, showcasing its engagement with the investment community. The company will hold fireside chats at both the Evercore ISI HealthconX Conference and the Piper Sandler Healthcare Conference. Cytokinetics is known for focusing on muscle biology-directed treatments, notably advancing aficamten for obstructive hypertrophic cardiomyopathy with promising Phase 3 trial results and upcoming regulatory submissions across the US, Europe, and China.
Read more →CYTKCytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has announced that the FDA has accepted its New Drug Application for aficamten, a cardiac myosin inhibitor aimed at treating obstructive hypertrophic cardiomyopathy (HCM). This acceptance is based on positive outcomes from the SEQUOIA-HCM Phase 3 trial, which indicated significant improvements in exercise capacity and other clinical endpoints. The FDA's target action date for this application is set for September 26, 2025. Aficamten has already been granted Breakthrough and Orphan Drug Designations, highlighting its promise in the treatment landscape.
Read more →CYTKCytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
Cytokinetics and Bayer have entered an exclusive licensing agreement for aficamten, a cardiac myosin inhibitor intended for the treatment of hypertrophic cardiomyopathy (HCM) in Japan. Cytokinetics will receive an upfront payment of €50 million, with potential milestone payments and royalties totaling up to €490 million. The collaboration includes conducting a Phase 3 trial in Japanese patients and expanding ongoing trials to support marketing authorization. This partnership aims to leverage Bayer's expertise in cardiovascular therapies to better serve patients in Japan.
Read more →CYTKCytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
Cytokinetics presented new data on Aficamten for treating hypertrophic cardiomyopathy (HCM) at the American Heart Association Scientific Sessions 2024. The findings demonstrated that Aficamten significantly improves post-exercise oxygen uptake recovery and quality of life for patients. Additionally, the drug durably reduced the percentage of patients eligible for septal reduction therapy. The analyses, including real-world data, also indicated disparities in healthcare costs associated with HCM based on sociodemographic factors.
Read more →CYTKCytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
Cytokinetics, Incorporated (CYTK) presented new data from post-hoc analyses of the GALACTIC-HF trial at the American Heart Association Scientific Sessions 2024. The analyses indicate that omecamtiv mecarbil may reduce the risk of adverse outcomes in heart failure patients, particularly those at higher risk, such as older patients or those with recent ventricular arrhythmias. The treatment was shown to maintain its efficacy across different age groups, and did not increase the occurrence of ventricular arrhythmias compared to placebo, suggesting a favorable safety profile. Cytokinetics is preparing to initiate a confirmatory Phase 3 trial, COMET-HF, to further evaluate the drug's potential benefits.
Read more →CYTKCytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
Cytokinetics, Inc. is scheduled to participate in the 2024 Jefferies London Healthcare Conference on November 19, 2024. The company plans to host a fireside chat accessible via a live webcast. Cytokinetics focuses on developing therapies for cardiovascular diseases and has submitted an NDA for its cardiac myosin inhibitor, aficamten, following positive results from the SEQUOIA-HCM trial. The company is also advancing multiple clinical trials for aficamten and other drug candidates aimed at improving cardiac muscle performance.
Read more →CYTKCytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
Cytokinetics has announced the start of a Phase 1 clinical study for its drug CK-089, a fast skeletal muscle troponin activator (FSTA) aimed at treating specific muscular dystrophy and related conditions. The initial dosing of participants has commenced in a randomized, double-blind, placebo-controlled trial design to assess CK-089's safety and pharmacokinetics. Preclinical studies indicated that CK-089 may enhance muscle force and function, establishing its potential application for patients suffering from neuromuscular diseases. The company continues to focus on its cardiology franchise while expanding its pipeline with innovative muscle biology-directed therapies.
Read more →CYTK▲ +5.7%on this newsshared move
Cytokinetics Reports Third Quarter 2024 Financial Results
Cytokinetics reported its third quarter 2024 financial results, highlighting the completion of the NDA submission for aficamten aimed at treating obstructive hypertrophic cardiomyopathy. The company anticipates the initiation of several key clinical trials, including COMET-HF for omecamtiv mecarbil and AMBER-HFpEF for CK-586, in the fourth quarter of 2024. With a solid cash reserve of approximately $1.3 billion, Cytokinetics is well-positioned to advance its cardiology-focused pipeline and sustain its growth into 2025.
Read more →CYTKCytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024
Cytokinetics, a biopharmaceutical company specializing in cardiovascular treatments, has announced six upcoming presentations at the American Heart Association Scientific Sessions 2024, scheduled for November 16-18 in Chicago. These presentations will highlight new findings related to their drug candidates, particularly aficamten, which has shown effective results in treating obstructive hypertrophic cardiomyopathy (HCM). The company is actively progressing its regulatory submissions for aficamten in the U.S. and Europe, following successful Phase 3 trial outcomes. Additionally, Cytokinetics continues to innovate in the field of heart failure therapies, including the development of omecamtiv mecarbil.
Read more →CYTKCytokinetics to Announce Third Quarter Results on November 6, 2024
Cytokinetics, Incorporated plans to announce its third quarter results on November 6, 2024, at 4:00 PM ET, followed by a management conference call discussing operational and financial results. The company is focused on developing drug candidates for cardiac muscle performance and has made significant progress with aficamten, a cardiac myosin inhibitor, having submitted an NDA to the U.S. FDA and progressing applications in Europe. Additional studies for aficamten are ongoing in various clinical settings for hypertrophic cardiomyopathy and heart failure therapies.
Read more →CYTKCytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
Cytokinetics, Incorporated is focusing on its cardiac myosin modulation programs and commercial launch preparations for aficamten, having recently submitted its New Drug Application to the FDA. The upcoming clinical trials, including COMET-HF and AMBER-HFpEF, aim to investigate new treatments for patients with heart failure and hypertrophic cardiomyopathy. The company is enhancing its market readiness through engaged stakeholder collaboration and educational campaigns for healthcare professionals. Today's Investor and Analyst Day showcased the company's progress and future directions in its specialty cardiology franchise.
Read more →CYTKCytokinetics to Host Investor & Analyst Day on October 16, 2024
Cytokinetics announced its Investor and Analyst Day set for October 16, 2024, focusing on cardiac myosin modulation and upcoming commercial launches. The event will highlight the company's programs, including aficamten, a cardiac myosin inhibitor for obstructive HCM. Senior leadership and expert clinicians will discuss advancements and strategies within their specialty cardiology initiatives. Registration is required for attendance, with a commitment to update stakeholders on significant developments in their research and commercial efforts.
Read more →CYTKCytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
Cytokinetics has announced positive results from additional analyses of its Phase 3 trial, SEQUOIA-HCM, focusing on aficamten in symptomatic obstructive hypertrophic cardiomyopathy (HCM). Presented at the Heart Failure Society of America Annual Scientific Meeting, the analyses highlighted substantial improvements in clinical outcomes for patients receiving aficamten compared to placebo. Key findings include 68% of patients achieving a complete hemodynamic response and 97% reaching at least one clinically relevant outcome. With plans for regulatory submissions, Cytokinetics aims to establish aficamten as a leading treatment option in this therapeutic area.
Read more →CYTKCytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
Cytokinetics announced positive data from the SEQUOIA-HCM trial, revealing significant improvements in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated with aficamten. The results included notable enhancements in cardiac structure and function, with a substantial percentage of patients experiencing beneficial effects. Notably, many improvements were observed when compared to placebo outcomes. However, the company withdrew a planned poster presentation due to weather-related circumstances.
Read more →CYTKCytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
Cytokinetics has announced its seventh annual Communications Grant Program, offering $100,000 in total funding to patient advocacy organizations focused on cardiovascular diseases. Each of the five selected organizations will receive a grant of $20,000 aimed at enhancing communication efforts and community engagement for hypertrophic cardiomyopathy and heart failure. Applications for the grants are due by November 4, 2024, with recipients to be announced in January 2025. The program underscores Cytokinetics' commitment to supporting underfunded nonprofit patient organizations in their outreach efforts.
Read more →CYTKCytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
Cytokinetics, Incorporated (Nasdaq: CYTK) has announced several presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting, both scheduled for late September 2024 in Atlanta, GA. Notably, they will present results from the SEQUOIA-HCM trial, which evaluates the efficacy of Aficamten in patients with obstructive hypertrophic cardiomyopathy. The findings are set to advance the understanding of treatment options within this specialized field. These presentations affirm Cytokinetics' focus on developing impactful therapies for cardiac muscle performance.
Read more →CYTKCytokinetics Announces Data From Phase 1 Study of CK-4021586
Cytokinetics has announced promising results from the Phase 1 study of CK-4021586 (CK-586), a cardiac myosin inhibitor aimed at treating heart failure with preserved ejection fraction (HFpEF). The trial demonstrated that CK-586 was safe and well-tolerated, with no serious adverse events reported. Based on these findings, the company plans to initiate a Phase 2 clinical trial in Q4 2024, targeting patients with HFpEF characterized by hypercontractility and ventricular hypertrophy. The study findings indicate a predictable pharmacokinetic profile, supporting potential future dosing regimens.
Read more →CYTKCytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
Cytokinetics, Inc. has announced two upcoming presentations at the 2024 American College of Clinical Pharmacology Annual Meeting. The presentations will cover a first-in-human study of CK-4021586, a cardiac myosin inhibitor, and a clinical evaluation of aficamten. Additionally, Cytokinetics is actively working on various clinical trials for aficamten and CK-586, aiming to improve treatment options for patients with heart conditions. The company is preparing for regulatory submissions following promising Phase 3 trial results.
Read more →CYTKCytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
Cytokinetics has presented new safety data for aficamten at the ESC Congress 2024, highlighting its promising long-term use for patients with hypertrophic cardiomyopathy (HCM). The data includes an integrated safety analysis from three clinical trials, reinforcing aficamten's robust safety profile and demonstrating that patients are able to successfully withdraw standard medications. The findings suggest aficamten could serve as an effective monotherapy without negative impacts on safety or treatment efficacy. Cytokinetics will share further results from the MAPLE-HCM trial in early 2025.
Read more →CYTKCytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
Cytokinetics presented additional data from the SEQUOIA-HCM trial at the European Society of Cardiology Congress 2024, highlighting the effectiveness of aficamten in improving cardiac structure and function in patients with symptomatic obstructive hypertrophic cardiomyopathy. The data indicated significant reductions in left ventricular mass and left atrial volume, as well as improvements in patient-reported symptoms. Accompanied by several publication releases in leading cardiac journals, these results support the potential of aficamten for disease modification and improve the overall quality of life for HCM patients. The company's rolling NDA submission for aficamten is expected to be completed this quarter.
Read more →CYTK▲ +5.4%on this news
CYTOKINETICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten; Company Has Initiated Rolling NDA Submission FDA Cleared Protocol Ame
Cytokinetics reported its financial results for Q2 2024, highlighting progress in the development of aficamten, a cardiac myosin inhibitor. The company received significant funding of over $1 billion to support aficamten's launch and ongoing clinical trials. Notably, the FDA has made amendments to monitoring protocols, which may facilitate the ongoing development of the drug. A rolling New Drug Application (NDA) submission for aficamten is underway, with plans to finalize submissions in Q4 2024.
Read more →CYTKCytokinetics Announces Call for Proposals for Corporate Giving Program
Cytokinetics has announced a call for proposals for its Corporate Giving Program aimed at expanding charitable donations to non-profit organizations. This program focuses on supporting diversity in science education and equitable healthcare initiatives for cardiovascular disease in local and at-risk communities. Organizations can apply for donations up to $20,000, with the application deadline set for September 16, 2024. The move aligns with Cytokinetics' long-standing commitment to corporate responsibility and patient advocacy.
Read more →CYTKCytokinetics to Announce Second Quarter Results on August 8, 2024
Cytokinetics, Inc. has announced the date for its second quarter results, scheduled for August 8, 2024. Following this announcement, a conference call will be held to discuss operational and financial results as well as the company's future outlook. The company continues to develop promising cardiac treatments, particularly aficamten, which has shown positive results in pivotal trials for obstructive hypertrophic cardiomyopathy.
Read more →CYTKCytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
Cytokinetics announced seven upcoming presentations at the European Society of Cardiology Congress 2024, including four late-breaking presentations on aficamten. These presentations will highlight new findings related to patient-reported health status, cardiac structure and function, and the safety of withdrawing standard care medications. The Congress will take place in London from August 30 to September 2, 2024. The announcements come on the heels of positive results from the pivotal Phase 3 SEQUOIA-HCM trial, supporting aficamten's potential as a treatment for obstructive hypertrophic cardiomyopathy.
Read more →CYTKCytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
Cytokinetics has announced the initiation of a Phase 1 study for Aficamten in healthy participants, including Japanese adults. This study aims to evaluate the pharmacokinetics, safety, and tolerability of the drug. Additionally, Cytokinetics is advancing its global clinical development program for Aficamten and preparing for regulatory submissions in the U.S. and Europe within the year. Aficamten is designed to address hypertrophic cardiomyopathy and has shown positive results in prior studies, including receiving Breakthrough Therapy Designation from the FDA.
Read more →CYTK▲ +12.7%on this news
As we had previously stated, throughout 2023, Cytokinetics engaged in Business Development discussions with potential strategic partners with respect to aficamten . Leading up to and after our late December 2023 disclosu
Cytokinetics has been in discussions regarding potential strategic partnerships for aficamten throughout 2023. Following recent clinical trial results, a third party expressed interest in acquiring Cytokinetics and negotiations commenced. However, the acquisition did not progress, and while the Board was supportive, no actionable proposal was ever finalized. The company emphasizes its commitment to shareholder value and provides a transparent overview of the situation, but states it will not comment further on the matter.
Read more →CYTKCytokinetics Announces Closing of Public Offering of Common Stock
Cytokinetics has successfully closed its underwritten public offering of 9,803,922 common shares at a price of $51.00 each, raising around $500 million in gross proceeds. The offering was managed by J.P. Morgan, Goldman Sachs & Co. LLC, and Morgan Stanley. This offering was made under the shelf registration statement filed with the SEC, which is now automatically effective. Relevant documents and prospectus have been filed and are accessible on the SEC's website.
Read more →CYTK▼ -17.3%on this newsshared move
Cytokinetics Announces Pricing of Public Offering of Common Stock
Cytokinetics has announced the pricing of a public offering of 9,803,922 shares of its common stock at $51.00 per share. The gross proceeds from this offering are expected to be around $500 million. The offering, managed by J.P. Morgan, Goldman Sachs, and Morgan Stanley, is set to close on May 28, 2024, pending customary closing conditions. Cytokinetics has also provided underwriters with a 30-day option to purchase additional shares.
Read more →CYTKEMPOWERING muscle EMPOWERING lives Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics, Incorpor
Cytokinetics has made significant strides in its drug development and financing by entering a $250M structured financing transaction with Royalty Pharma. The company is focused on preparing for regulatory submissions for its lead drug candidate, aficamten, expected in the second half of 2024. Despite the positive outlook, the company acknowledges challenges that include potential delays in clinical trials and the need for regulatory approvals. Nonetheless, Cytokinetics aims to establish itself as a leader in developing innovative treatments for diseases affecting muscle function.
Read more →CYTKCytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Cytokinetics and Royalty Pharma announced an expanded strategic funding collaboration totaling up to $575 million. The funding aims to support the commercialization of aficamten and enhance Cytokinetics' cardiovascular pipeline. Key components include upfront capital for clinical trials and royalty restructuring, indicating a strong belief in the pipeline's potential. The partnership capitalizes on the demonstrated clinical success of aficamten in trials, while also emphasizing the importance of advancing other drug candidates within the company’s portfolio.
Read more →CYTKCytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
Cytokinetics is hosting the Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on May 17, 2024, in San Francisco. The event aims to engage researchers and students in discussion and collaboration on muscle biology. Notable speakers include experts from various prestigious institutions, and the symposium aims to advance understanding and treatment of muscle-related disorders. Cytokinetics is also preparing for regulatory submissions and advancing clinical trials for its cardiac drug candidates.
Read more →CYTKCytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
Cytokinetics, Inc. has announced plans for five presentations related to its drug aficamten at the European Society of Cardiology Congress 2024, scheduled for late August to early September in London, UK. The presentations will focus on various aspects of aficamten's effects on obstructive hypertrophic cardiomyopathy, including its clinical application, safety analysis, and impact on patient-reported health status. The company is moving forward with regulatory submissions based on positive outcomes from the SEQUOIA-HCM Phase 3 clinical trial, signaling progress in its therapeutic developments.
Read more →CYTK▼ -6.8%on this newsshared move
CYTOKINETICS ANNOUNCES PRIMARY RESULTS FROM SEQUOIA-HCM PRESENTED IN LATE BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2024 CONGRESS AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDI
Cytokinetics announced promising results from the SEQUOIA-HCM trial of aficamten, a treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM), which showed significant improvements in exercise capacity and symptoms. The trial demonstrated enduring positive effects across multiple subgroups and endpoints, with patients experiencing rapid and sustained benefits. Importantly, aficamten was well tolerated, with no treatment interruptions due to low left ventricular ejection fraction (LVEF). The findings were presented at the European Society of Cardiology Congress and published in the New England Journal of Medicine.
Read more →CYTK▼ -6.8%on this newsshared move
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics has announced additional results from the SEQUOIA-HCM trial for aficamten, presented at the European Society of Cardiology's Heart Failure 2024 Congress. The trial demonstrated improvements in dosing, safety, and exercise performance in patients with obstructive hypertrophic cardiomyopathy. Key findings indicated a strong correlation between exercise performance and clinical improvement, with low adverse event rates. The company is scheduled to host an investor event to discuss these findings further.
Read more →CYTKCYTOKINETICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart
Cytokinetics reported its financial results for the first quarter of 2024, highlighting a net loss of $135.6 million, an increase from the previous year. The company made progress with its muscle-biology portfolio, including the initiation of the CEDAR-HCM clinical trial in pediatric patients. Additional analyses from the SEQUOIA-HCM study are set for presentation at the European Society of Cardiology Heart Failure Congress. Revenue also saw a notable decline compared to the previous year, primarily attributed to reduced milestone and collaboration revenues.
Read more →CYTKCytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has announced the start of CEDAR-HCM, a clinical trial evaluating aficamten in a pediatric population suffering from symptomatic obstructive hypertrophic cardiomyopathy (HCM). This trial is intended to assess the safety and efficacy of aficamten and is pivotal as HCM poses significant health risks in children and adolescents. The trial will initially enroll approximately 40 adolescent patients, with an expansion cohort planned for younger children. Results from this study may offer new therapeutic options for managing this serious genetic condition impacting young patients.
Read more →CYTKCytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
Cytokinetics has announced positive topline data from its Phase 1 study of CK-4021586 (CK-586), which evaluated the safety, tolerability, and pharmacokinetics in healthy participants. The results indicate that CK-586 is ready for advancement to a Phase 2 clinical trial targeting heart failure with preserved ejection fraction (HFpEF), expected to start in Q4 2024. The study demonstrated CK-586's safety profile, and no serious adverse events were reported, making it a promising candidate in specialty cardiology. Full data from the Phase 1 study is slated for presentation at a medical congress in the second half of 2024.
Read more →CYTKCytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics will hold an investor event on May 13, 2024, to discuss the primary results from its SEQUOIA-HCM trial, which focuses on treatment for obstructive hypertrophic cardiomyopathy. The results will be presented during a Late Breaking Clinical Trial session at the European Society of Cardiology Heart Failure Congress 2024 in Lisbon. The event aims to provide insights on the drug aficamten and its potential impact on cardiac muscle performance.
Read more →CYTKCytokinetics to Announce First Quarter Results on May 8, 2024
Cytokinetics, Inc. is set to announce its first quarter results on May 8, 2024, with a follow-up conference call to discuss the results at 4:30 PM ET. The company is focused on developing innovative treatments for heart conditions, including aficamten, which has shown positive results in a Phase 3 trial. Additionally, Cytokinetics is engaged in various research and development activities for several cardiac therapies. As with any biopharma entity, there are inherent risks and uncertainties surrounding its forward-looking statements and future performance.
Read more →CYTKCytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics, Incorporated has announced three Late Breaking Clinical Trial presentations at the upcoming Heart Failure 2024 Congress in Lisbon, Portugal. These presentations relate to the SEQUOIA-HCM trial, which explores the efficacy and safety of aficamten for patients with obstructive hypertrophic cardiomyopathy. The company reported positive topline results from this pivotal Phase 3 trial, further emphasizing its commitment to advancing treatments for cardiovascular diseases. The timeline for regulatory submissions for aficamten will follow these promising results.
Read more →CYTKCytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Cytokinetics, Incorporated announced that CEO Robert I. Blum will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 8, 2024. The company is focused on developing therapies for cardiac muscle performance and is preparing for regulatory submissions for aficamten after positive clinical trial results. Additionally, Cytokinetics is advancing several other drug candidates aimed at treating various heart failure conditions. Interested parties can access the live webcast and its replay on the company's website.
Read more →CYTKCytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
Cytokinetics, Incorporated (Nasdaq: CYTK) has announced four presentations at the upcoming American College of Cardiology 73rd Annual Scientific Session, set for April 6-8, 2024, in Atlanta, GA. These presentations will focus on various studies related to hypertrophic cardiomyopathy, particularly the efficacy and safety of aficamten. Notably, the company is preparing for regulatory submissions for aficamten following successful outcomes from its pivotal Phase 3 clinical trial, SEQUOIA-HCM. Cytokinetics continues to advance its pipeline, which includes multiple ongoing clinical trials for cardiovascular conditions.
Read more →CYTKCytokinetics Joins Global Initiative to Recognize International Rare Disease Day
Cytokinetics has announced its participation in Rare Disease Day, joining organizations such as EURORDIS and NORD to raise awareness about rare diseases affecting over 300 million people globally. The initiative emphasizes the need for equitable access to diagnosis and treatment. CEO Robert I. Blum expressed pride in this partnership while also highlighting the company's ongoing efforts to advance aficamten, a treatment for obstructive hypertrophic cardiomyopathy, with regulatory submissions planned for later this year.
Read more →CYTK▼ -9.8%on this newsshared move
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
Cytokinetics, in collaboration with The Mended Hearts, Inc. and WomenHeart, has launched the ENACT initiative aimed at increasing engagement in cardiovascular clinical trials. This initiative focuses on promoting awareness and reducing barriers for historically underrepresented groups in clinical research, particularly women and people of color. ENACT will provide educational resources, including videos and guides, as well as peer support training to empower patients. The program aims to adapt and expand based on the needs of the communities served by the partnering organizations.
Read more →CYTKCYTOKINETICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Impro
Cytokinetics reported its fourth quarter and full-year financial results for 2023, highlighting positive topline data from the SEQUOIA-HCM study which demonstrated significant improvements in efficacy endpoints for aficamten. The company plans to submit a New Drug Application to the FDA in Q3 2024 and a Marketing Authorization Application to the EMA in Q4 2024. Despite a net loss of $526 million for the year and a decrease in revenue, Cytokinetics maintains a strong cash position with substantial runway for further development.
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on February 27, 2024
Cytokinetics, a late-stage biopharmaceutical company, is set to announce its fourth quarter results on February 27, 2024, followed by a conference call for discussion. The call will be available via webcast and telephone. The company is notably working on its cardiac myosin inhibitor aficamten, which has demonstrated positive results in significant clinical trials. Additionally, Cytokinetics is developing various other drug candidates targeting heart failure and muscle performance.
Read more →CYTKCytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Cytokinetics, Inc. announced that CEO Robert I. Blum will participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company, focused on cardiovascular diseases, is preparing for regulatory actions regarding aficamten, a cardiac myosin inhibitor, following promising results from its Phase 3 clinical trial. In addition to aficamten, Cytokinetics is developing other treatments aimed at improving muscle performance in the heart.
Read more →CYTKCytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
Cytokinetics, Incorporated (Nasdaq: CYTK) recently announced the recipients of its sixth annual Communications Grant Program, awarding five patient advocacy organizations with $20,000 each. These grants aim to enhance communication and awareness for the hypertrophic cardiomyopathy (HCM), heart failure, and amyotrophic lateral sclerosis (ALS) communities. The funded projects will focus on resource access and educational initiatives. Cytokinetics continues to demonstrate its commitment to patient advocacy through this support.
Read more →CYTKCytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
Cytokinetics has presented new data at CMR 2024 from the FOREST-HCM trial, demonstrating the positive effects of aficamten on patients with hypertrophic cardiomyopathy (HCM). The findings indicate that treatment led to significant improvements in cardiac structure, function, and stabilization of myocardial fibrosis over 48 weeks. This builds on previous data, supporting aficamten’s profile as a promising treatment option in this patient population. The ongoing research aims to further assess the long-term benefits of this investigational drug.
Read more →CYTKCytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
Cytokinetics has announced a significant presentation planned for CMR 2024, focusing on aficamten's impact on patients with obstructive hypertrophic cardiomyopathy. This presentation will be led by Dr. Ahmad Masri and is scheduled for January 25, 2024, in London. The company, recognized for its pioneering work in muscle biology, continues to advance its late-stage clinical trials, including positive outcomes from its pivotal Phase 3 SEQUOIA-HCM trial. Additionally, Cytokinetics is working on various other drug candidates aimed at improving cardiac muscle function.
Read more →CYTKCytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Cytokinetics announced that CEO Robert I. Blum will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The company, known for its late-stage cardiovascular biopharmaceuticals, is advancing several drug candidates focused on improving cardiac muscle performance. Notably, aficamten is preparing for regulatory interactions following positive results from its pivotal Phase 3 trial. In addition, Cytokinetics is exploring other treatments for heart failure and obstructive hypertrophic cardiomyopathy.
Read more →CYTK▲ +82.5%on this newsshared move
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced positive topline results from the SEQUOIA-HCM Phase 3 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy. The trial demonstrated statistically significant and clinically meaningful improvements in exercise capacity and secondary endpoints, indicating the drug's effectiveness. Aficamten was well-tolerated, with an adverse event profile comparable to placebo, and no disruptions to treatment due to low left ventricular ejection fraction. Details of the full results will be presented at an upcoming medical conference.
Read more →CYTKCytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
Cytokinetics, Incorporated announced an investor call scheduled for December 27, 2023, to present the topline results of the SEQUOIA-HCM trial. This Phase 3 clinical trial evaluates aficamten, an investigational drug for symptomatic obstructive hypertrophic cardiomyopathy (HCM). The call will be available via webcast and telephone, with an archived replay accessible for twelve months. Cytokinetics is dedicated to developing treatments for cardiac muscle performance, positioning itself as a leader in muscle biology and innovative therapies.
Read more →CYTKCytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND
Cytokinetics presented the results from the COURAGE-ALS trial at an international symposium, highlighting the discontinuation of the study due to futility. The trial assessed the investigational drug reldesemtiv for ALS but showed no significant efficacy on primary endpoints, leading to the decision to stop further development. While the trial's innovative design features were favorably received by participants, the overall results are disappointing and underscore the challenges in finding effective ALS treatments.
Read more →CYTKCytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND
Cytokinetics, Incorporated has announced its participation in the 34th International Symposium on ALS/MND with five presentations scheduled from December 6-8, 2023. These presentations will cover various aspects of ALS clinical trials, including findings from the Phase 3 COURAGE-ALS trial and related research like plasma neurofilament analysis. The event showcases Cytokinetics' ongoing commitment to advancing treatments for neuromuscular diseases and muscle biology innovations.
Read more →CYTKCYTOKINETICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS On Track for Topline Results from SEQUOIA-HCM a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM, in Late December Long-Term Data from FOREST-HCM, t
Cytokinetics reported its financial results for the third quarter of 2023, showing a net loss of $129.4 million, which reflects some financial challenges compared to the previous year's losses. The company is focused on its pipeline, particularly the Aficamten trials, showing promising long-term data from the FOREST-HCM trial and moving forward with the ACACIA-HCM trial. Despite a revenue decrease, Cytokinetics reported a strong cash position and continues to make strides in its speciality cardiology programs.
Read more →CYTKCytokinetics to Participate in Upcoming Investor Conferences
Cytokinetics, Inc. announced its participation in a series of investor conferences in November 2023. Key events include discussions on muscle-targeting approaches and the company's pioneering work in muscle biology. Executives will engage in fireside chats and panel discussions at notable conferences such as the UBS BioPharma Conference and the Truist Securities BioPharma Symposium. The company's focus is on developing therapies for cardiovascular conditions, particularly those affecting muscle performance.
Read more →CYTKCytokinetics to Announce Third Quarter Results on November 2, 2023
Cytokinetics, Incorporated announced it will report its third quarter financial results on November 2, 2023. Following this announcement, a conference call with senior management is scheduled to discuss the operational and financial results, along with future company outlook. Cytokinetics is focused on developing innovative cardiac treatments targeted at improving muscle performance, including several candidates currently in Phase 3 clinical trials. The company celebrates 25 years in the field, emphasizing its commitment to combating muscle-related diseases.
Read more →CYTKCYTOKINETICS, All Rights Reserved. CYTOKINETICS and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Forward-Looking Statements This Presentation contains forward-looki
Cytokinetics provided an update through a presentation addressing their forward-looking statements and research activities in heart failure and hypertrophic cardiomyopathy (HCM). The company emphasizes its development programs for aficamten and omecamtiv mecarbil while projecting potential market opportunities. However, they also noted various risks including potential delays in clinical trials, regulatory approvals, and the possibility of adverse effects from their drug candidates. The presentation highlighted their commitment to building a specialty cardiology franchise to address segments of the patient population in need of new therapies.
Read more →CYTKCytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
Cytokinetics, at its virtual Investor and Analyst Day, provided updates on its cardiac myosin inhibitor programs, particularly Aficamten. The company shared new long-term efficacy data and insights into commercial readiness as it prepares for the potential launch of Aficamten for hypertrophic cardiomyopathy. Additionally, preclinical data for CK-586 was presented, showcasing its potential in treating heart failure with preserved ejection fraction. Key opinions from leading physicians and patient perspectives were also highlighted during the event.
Read more →CYTK▲ +11.4%on this news· ran to +31% by day 3
Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions
Cytokinetics presented the baseline characteristics of patients enrolled in the SEQUOIA-HCM trial at the HCM Society Scientific Sessions. The pivotal Phase 3 study evaluates aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. The trial included 282 participants, predominantly from Europe and the U.S., and anticipates topline results by the end of 2023. These findings will contribute to understanding aficamten's potential impact on cardiac function and patient symptoms.
Read more →CYTKCytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023
Cytokinetics, Inc. announced a virtual Investor and Analyst Day scheduled for October 19, 2023, focused on advancements in cardiac therapies. The event, titled 'New Horizons in Hypercontractility,' will feature presentations on their cardiac myosin inhibition programs, including longer-term data from the FOREST-HCM study and updates on the company's commercial strategies. Notably, expert panels will discuss the current landscape of hypertrophic cardiomyopathy and patient perspectives on living with the condition.
Read more →CYTK▼ -5.4%on this newsshared move
Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
Cytokinetics announced its participation in the 2023 HCMS Scientific Sessions and HFSA Annual Scientific Meeting, taking place in Cleveland, OH, from October 6-9, 2023. The company will present several posters related to its Phase 3 clinical trials, particularly on its cardiac myosin inhibitor, Aficamten, and other studies on hypertrophic cardiomyopathy. This event marks an opportunity for the company to share significant findings in the field of cardiovascular health. Cytokinetics continues to innovate by focusing on muscle performance and related treatments.
Read more →CYTKCytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program
Cytokinetics has announced the sixth annual Communications Grant Program, offering $100,000 in total to support patient advocacy organizations focused on cardiovascular and neuromuscular diseases. The program will allocate five grants of $20,000 each to eligible organizations, with applications due by November 1, 2023. The initiative is designed to enhance communication capacities, raise awareness, and engage communities around diseases such as hypertrophic cardiomyopathy and amyotrophic lateral sclerosis. Grant recipients will be announced in January 2024.
Read more →CYTKCytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Cytokinetics announced the initiation of the ACACIA-HCM trial, a pivotal Phase 3 clinical study of aficamten aimed at treating symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). The trial will enroll 420 patients and assess the drug's impact on quality of life and various health endpoints over 72 weeks. This marks a significant step in evaluating aficamten's therapeutic potential, building on prior encouraging Phase 2 results related to heart failure symptoms. The trial design includes both primary and secondary endpoints focusing on exercise performance and cardiac function measures.
Read more →CYTKCYTOKINETICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year Initiated Enrollm
Cytokinetics reported its financial results for Q2 2023, highlighting significant progress in its clinical trials, especially with aficamten. The company completed enrollment in the SEQUOIA-HCM trial, the largest of its kind for hypertrophic cardiomyopathy (HCM), and expects topline results by the end of the year. Additionally, Cytokinetics initiated enrollment in a second pivotal trial (MAPLE-HCM) and revised its financial guidance, projecting operating expenses between $390 and $410 million. However, the company faced an increase in net losses compared to the previous year.
Read more →CYTKCytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Cytokinetics, Inc. announced the granting of stock options to three new employees as an inducement for their employment. The total options granted amount to 60,200 shares, with a strike price set at $33.35 per share. These options will vest over a four-year period, showing the company's commitment to long-term employee incentives. Cytokinetics continues to focus on developing treatments for cardiovascular diseases, further underlined by its current clinical trials for their drug candidates.
Read more →CYTKCytokinetics to Announce Second Quarter Results on August 3, 2023
Cytokinetics, Inc. will announce its second quarter results on August 3, 2023, with a conference call scheduled shortly after. The call will discuss both operational and financial outcomes, alongside the company’s future endeavors. Known for its specialization in cardiovascular treatments, Cytokinetics is advancing several drug candidates, including aficamten for hypertrophic cardiomyopathy and omecamtiv mecarbil for heart failure. This year marks the company's 25-year anniversary in the muscle biology sector.
Read more →CYTKCytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has initiated the MAPLE-HCM trial, a Phase 3 study comparing aficamten, a cardiac myosin inhibitor, with metoprolol, a beta blocker, in treating symptomatic obstructive hypertrophic cardiomyopathy (HCM). This trial is significant as it is the first to evaluate aficamten in a head-to-head comparison with a widely used therapy. The primary endpoint focuses on the change in exercise capacity, with the study expected to enroll 170 patients. The company aims for aficamten to demonstrate superior outcomes compared to metoprolol, potentially simplifying treatment approaches for HCM patients.
Read more →CYTKCYTOKINETICS PRESENTS NEW DATA IN PATIENTS WITH NON-OBSTRUCTIVE HCM FROM COHORT 4 OF REDWOOD-HCM IN LATE-BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2023 CONGRESS Treatment of Afic
Cytokinetics presented new data from its REDWOOD-HCM trial at the European Society of Cardiology Heart Failure 2023 Congress, showcasing treatment effects of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The results indicated statistically significant improvements in patient-reported outcomes and biomarker levels, with a favorable safety profile. Aficamten is positioned for further investigation in a Phase 3 clinical trial scheduled to commence in the second half of 2023.
Read more →CYTKCytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress
SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one Late Breaking Clinical Trial presentation and two moderated ePoster presentations at Heart Failure 2023 an International Congress of the European Society of
Read more →CYTKCytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical s
Read more →CYTKCytokinetics to Participate in the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the JMP Securities Life Sciences Conference on Mon
Read more →CYTKCYTOKINETICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS SEQUOIA-HCM Nearing Completion of Enrollment; On Track for Results in Q4 2023 Additional Data from Cohort 4 of REDWOOD-HCM to be Presented in Late-Breaking Clinic
Cytokinetics reported its financial results for Q1 2023, revealing a net loss of $131.3 million. The company is nearing completion of patient enrollment in its pivotal Phase 3 SEQUOIA-HCM trial, with results expected in Q4 2023. Additionally, revenue has increased, partly due to a milestone payment. Despite positive advancements, the company faces challenges, including the FDA's Complete Response Letter regarding omecamtiv mecarbil.
Read more →CYTKCytokinetics to Announce First Quarter Results on May 4, 2023
SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will
Read more →CYTKCytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Confe
Read more →CYTKCytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis
Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., March 31, 20
Read more →CYTKCytokinetics Releases Inaugural Corporate Responsibility Report
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the release of its inaugural Corporate Responsibility Report, outlining the Company's commitment to social and environmental responsibility, ethics and govern
Read more →CYTK▼ -6.7%on this newsshared move
Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement to Phase 3 Additional Results from FOREST-HCM Demonstrate Long-Term Treatment with Aficamten for 48 Weeks i
Read more →CYTKCYTOKINETICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the Ameri
Cytokinetics reported its financial results for Q4 2022, showing a significant net loss of $137.4 million and receiving a Complete Response Letter from the FDA for its drug omecamtiv mecarbil. Despite the negative regulatory feedback, the company continues to advance multiple clinical trials, including aficamten in hypertrophic cardiomyopathy and reldesemtiv in ALS. The company holds a strong cash position of $829.3 million as it prepares for future milestones and ongoing research activities.
Read more →CYTKCytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
Complete Response Letter States that GALACTIC-HF Alone Does not Establish Substantial Evidence of Effectiveness Sufficient for Approval Company Expects to Request Meeting with FDA to Discuss Potential Next Steps Cytokinetics to Host Conference Call and Webcast on March 1, 2023
Read more →CYTKCytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the American College of Cardiology 72nd Annual Scientific Session (ACC.23) taking place in New Orleans, LA from March 4, 2023 – M
Read more →CYTKCompensation Information for the Company's Named Executive Officers Robert I. Blum, President & Chief Executive Officer: 2023 base salary $790,000; 2022 bonus award $395,705; and 2023 target bonus is 75% of base salary.
The article outlines the compensation details for key executive officers of the company, particularly focusing on Robert I. Blum, the President and CEO. Blum's base salary for 2023 is noted to be $790,000, with a bonus award from the previous year amounting to $395,705. Additionally, the target bonus for 2023 is set at 75% of his base salary. Similar compensation details for other executive officers are also mentioned but not elaborated upon.
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on March 1, 2023
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 1, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wil
Read more →CYTKCytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its fifth annual Communications Grant Program, intended to support communications, awareness building and community engagement for nonprofit
Read more →CYTKForward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obliga
Cytokinetics has released a presentation outlining its forward-looking statements and plans under the Private Securities Litigation Reform Act. The company is focused on its research and development efforts for therapies aimed at treating heart failure, hypertrophic cardiomyopathy, and amyotrophic lateral sclerosis. It has laid out ambitious goals for regulatory approvals and expanding its drug pipeline, while also acknowledging the various risks and uncertainties involved in the drug development process.
Read more →CYTKCytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9,
Read more →CYTK▲ +8%on this news
Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil
PDUFA Target Action Date is February 28, 2023 Cytokinetics to Host Conference Call and Webcast on December 14, 2022 at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Foo
Read more →CYTK▲ +8%on this news
Cytokinetics Stock Trading Halted Today
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Nasdaq has halted the trading of the Company’s common stock. The U.S. Food & Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (
Read more →CYTKCytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review th
Read more →CYTKCytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND
Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score Strongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for COURAGE-ALS Will Enrich for the Enrollment of Faster Progressors SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- C
Read more →CYTKCytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study of CK-
Read more →CYTKCytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one poster presentation at the Virtual 33rd International Symposium on ALS/MND taking place online from December 6, 2022 - December 9, 2022 relating to surviva
Read more →CYTKCytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from two additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure),
Read more →CYTK▼ -5.1%on this newsshared move
CYTOKINETICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on
CYTOKINETICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 SEQUOIA-HCM Continuing with Results Expected in 2H 2023; Patient Screening for Coh
Read more →CYTKCytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming poster presentations at the American Heart Association Scientific Sessions 2022 taking place in Chicago, IL from November 5, 2022 - November 7,
Read more →CYTKCytokinetics to Announce Third Quarter Results on November 3, 2022
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2022 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management w
Read more →CYTKCytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring Committee (DMC) for COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), recently convened to
Read more →CYTK▲ +5.5%on this newsshared move
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life Additional Data Presented in Poster Session Shows Patients with Worsening Heart Failure and LVEF ≤30% Have Disproportionately High Risk of Heart Failure Hospitalization SOUTH SAN F
Read more →CYTKCytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today presented new data on the reduction and withdrawal of background standard of care medical therapy in patients treated with aficamten in REDWOOD-HCM OLE (Randomized Eval
Read more →CYTKCytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 11th, 2022 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cytoki
Read more →CYTK▼ -5.7%on this newsshared move
Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations, including two presentations at the 2022 Inaugural HCM Society Scientific Sessions, held by this newly launched professional medica
Read more →CYTK▲ +9.1%on this news· ran to +23% by day 3
CYTOKINETICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for
CYTOKINETICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending fo
Read more →CYTK▲ +9.1%on this news· ran to +23% by day 3
Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials
SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced a new release of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from
Read more →CYTKCytokinetics to Announce Second Quarter Results on August 4, 2022
SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 4, 2022 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wi
Read more →CYTKCytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering
SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $450.0 million aggregate principal amount of 3.50% convertible senior notes due 2027 (the “notes”) in a private
Read more →CYTKCYTOKINETICS
CYTOKINETICS ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) Cytokinetics, Incorporated ( Cytokinetics ) (Nasdaq: CYTK) today announced its intention to offer, subject to market and other conditions, $450.0 millio
Read more →CYTKCytokinetics Announces Proposed Convertible Senior Notes Offering
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2027
Read more →CYTKCytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
SOUTH SAN FRANCISCO, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the previously announced meeting of the Cardiovascular and Renal Drugs Advisory
Read more →CYTKCytokinetics Provides Regulatory Update for Omecamtiv Mecarbil
SOUTH SAN FRANCISCO, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the company recently provided additional pharmacokinetic analyses of omecamtiv
Read more →CYTKCytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS
SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of COURAGE-ALS OLE (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS Open Label Extension), an open-label extension clin
Read more →CYTKCytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
Echocardiographic Data Show Treatment with Aficamten for 10 Weeks Results In Improved Cardiac Structure, Myocardial Relaxation and Mitral Valve Mechanics SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced tha
Read more →CYTKCytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) relating to th
Read more →CYTKCytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class, Symptoms, and Biomarkers Analyses from GALACTIC-HF Show Patients with Low Blood Pressure Have Increased Treatment Effect SO
Read more →CYTK▼ -8.3%on this newsshared move
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2022 ALS Roundtables, t
Read more →CYTKCytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 2022 H.C. Wainwright Global Life Sciences Conference taking
Read more →CYTKCytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S. Food & Drug Administration (FDA) and was informed that the Agency plans to
Read more →CYTKCytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an International Congress of the European Society of Cardiology taking place online and in Madr
Read more →CYTKCytokinetics Reports First Quarter 2022 Financial Results
Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch Readiness Activities and Buildout of Commercial Infrastructure in Advance of PDUFA Date of November 30, 2022 for Omecamtiv Mecar
Read more →CYTKCytokinetics to Announce First Quarter Results on May 4, 2022
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2022 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will
Read more →CYTKCytokinetics Announces Changes to Board of Directors
L. Patrick Gage, Ph.D. to Retire from Board John T. Henderson, M.B., Ch.B. Named Chairman of Board Robert A. Harrington, M.D. Appointed to Board SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced changes to
Read more →CYTK▲ +5.4%on this newsshared move
Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Confe
Read more →CYTKCytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF Healthcare Resource Utilization and Cost Analysis from GALACTIC-HF Demonstrate Treatment with Omecamtiv Mecarbil Led to 19% Cost Reduction Per Patie
Read more →CYTKCytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session
SOUTH SAN FRANCISCO, Calif., April 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical t
Read more →CYTKCytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 71st Annual Scientific Session & Expo (ACC.22) taking place in Washington, D.C. from April 2, 2022 -
Read more →CYTKCytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 c
Read more →CYTK▲ +8.3%on this newsshared move
Cytokinetics Reports Fourth Quarter 2021 Financial Results
Commercial Launch Readiness Activities Underway for Omecamtiv Mecarbil in Advance of PDUFA Date of November 30, 2022 SEQUOIA-HCM Open to Enrollment; Development Program for Aficamten Expanding in 2022 Company Provides 2022 Financial Guidance; More Than 2 Years of Cash Runway
Read more →CYTK▼ -6.9%on this newsshared move
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 clinical trial of aficamten in patient
Read more →CYTKCytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease
SOUTH SAN FRANCISCO, Calif. and OAKLAND, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-year collaboration to accelerate education and awareness of heart disease. Within
Read more →CYTK▼ -6.8%on this newsshared move
Cytokinetics Announces Topline Results From METEORIC-HF
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction Results Will Be Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 71st Annual Scientific Session & Expo NDA for Omecamtiv Me
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on February 24, 2022
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2022 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management
Read more →CYTK▲ +5%on this news· ran to +22% by day 3
Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction
PDUFA Target Action Date Set for November 30, 2022 FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.
Read more →CYTKCytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM
Aficamten Reduced LVOT Gradients in Patients on Disopyramide With No Instances of Left Ventricular Ejection Fraction Below 50% Findings Support Inclusion of Patients on Disopyramide in SEQUOIA-HCM SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Inc
Read more →CYTKCytokinetics Announces Recipients of Fourth Annual Communications Fellowship Grants
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its fourth annual Communications Fellowship Grant program, intended to support increased capacity in communications, awareness building and c
Read more →CYTK▼ -9.4%on this newsshared move
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Easte
Read more →CYTKCytokinetics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday,
Read more →CYTKCytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
JI XING to Develop and Commercialize Novel Cardiac Myosin Activator in Patients with Heart Failure Cytokinetics to Receive $70 Million in Committed Capital; Up to an Additional $330 Million in Potential Milestone Payments Plus Royalties Cytokinetics to Host Conference Call an
Read more →CYTKCytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND including an analysis of baseline characteristics from the initial patients enrolle
Read more →CYTK▼ -5.5%on this newsshared move
Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for Aficamten
SOUTH SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic obstructive hypertrophic c
Read more →CYTKCytokinetics Announces Four Presentations at the 32nd International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32nd International Symposium on ALS/MND taking place online from December 7 – December 10, 2021. S
Read more →CYTKCytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare
Read more →CYTKCytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021
Analysis from GALACTIC-HF Shows Treatment with Omecamtiv Mecarbil Associated with Significant Reduction in the Risk of Stroke Data on Analog to CK-3828136 Adds Preclinical Support for Cardiac Troponin Activation as Novel Mechanism to Increase Cardiac Function without Impacting
Read more →CYTKCytokinetics Announces Two Presentations at the AHA Scientific Sessions 2021
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two presentations at the American Heart Association (AHA) Scientific Sessions 2021, taking place online from November 13, 2021 – November 15, 2021, including t
Read more →CYTK▲ +5.7%on this news· ran to +18% by day 3shared move
Cytokinetics Reports Third Quarter 2021 Financial Results
Submission of NDA for Omecamtiv Mecarbil on Track to Occur in Q4 2021 Start-Up Activities Underway for SEQUOIA-HCM Enrollment Complete in Cohort 3 of REDWOOD-HCM; Results Expected in Q1 2022 SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorpora
Read more →CYTKCytokinetics Announces Preclinical Data Relating to CK-3828136 Presented at the 2021 Medicinal Chemistry Gordon Research Conference
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data relating to the discovery and optimization of CK-3828136 (CK-136) were presented at the 2021 Medicinal Chemistry Gordon Research Conferen
Read more →CYTKCytokinetics Announces Preclinical Data for CK-3828136 to Be Presented at the 2021 Medicinal Chemistry Gordon Research Conference
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to the discovery and optimization of CK-3828136 (CK-136) will be presented at the 2021 Medicinal Chemistry Gordon Research Conference, takin
Read more →CYTKCytokinetics to Announce Third Quarter Results on November 3, 2021
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management w
Read more →CYTK▲ +7.6%on this news
Program to begin at 8:30 AM ET N o t F o r P r o m ot io n a l U s e , F o r I n v e s t o r s O n ly
Program to begin at 8:30 AM ET N o t F o r P r o m ot io n a l U s e , F o r I n v e s t o r s O n ly Forward - Looking Statements Charting the Commercial Course : Analyst & Investor Day 2021 N o t fo r P r o m ot i o n a l U s e , F o r I n v e s t o r s O n l y 2 This Presenta
Read more →CYTK▲ +7.6%on this news
Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline at Today’s Analyst & Investor Day
Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and Support Clinical Trial Design Announced for SEQUOIA-HCM, Phase 3 Clinical Trial of Aficamten Expected to Begin in Q4 Compan
Read more →CYTKCytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 12th, 2021 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cytokin
Read more →CYTKCytokinetics to Host Analyst & Investor Day on October 7, 2021
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host an Analyst and Investor Day on Thursday, October 7, 2021 from 8:30 AM to 11:30 AM ET. The event will be held at the Westin Grand Central Ho
Read more →CYTK▲ +6.6%on this news
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten Supporting Progression to Phase 3 Clinical Trial Additional Results from GALACTIC-HF Show Effect of Tre
Read more →CYTKCytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host a conference call and webcast on September 13, 2021 at 8:30 AM Eastern Time to discuss the full results from REDWOOD-HCM (Randomized Evaluation o
Read more →CYTKCytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting
Full Results from REDWOOD-HCM Expand on Positive Topline Results of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Additional Results from GALACTIC-HF Assess the Effect of Omecamtiv Mecarbil in Black Patients with Heart Failure with Reduced Ejection Fraction
Read more →CYTKCytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
SOUTH SAN FRANCISCO, Calif. and ELK GROVE VILLAGE, Ill., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Cure SMA today announced the renewal of their partnership to increase education, awareness, public policy and fundraising for spinal muscular a
Read more →CYTKCytokinetics Reports Second Quarter 2021 Financial Results
Submission of NDA for Omecamtiv Mecarbil on Track to Occur in 2H 2021 Positive Results from REDWOOD-HCM Support Progression of Aficamten (CK-274) to Pivotal Phase 3 Trial in Patients with Obstructive Hypertrophic Cardiomyopathy Expected to Start in Q4 Pivotal Phase 3 Trial of R
Read more →CYTKCytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Decline of SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo Company Is Planning to Provide Continued Access to Patients Who Complete COURAGE-ALS and Patients Who Previously Particip
Read more →CYTKCytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $27.50 per share. Thi
Read more →CYTKCytokinetics to Announce Second Quarter Results on August 5, 2021
SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 5, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wi
Read more →CYTK▲ +40.4%on this news· ran to +57% by day 3shared move
Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update
Sarcomere Directed Therapies Exhibit Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-lookin
Read more →CYTK▲ +40.4%on this news· ran to +57% by day 3shared move
Cytokinetics Announces Positive Topline Results of Redwood-HCM
Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy No Treatment Interruptions or Discontinuations Due to Reduction in
Read more →CYTKCytokinetics Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) were presented
Read more →CYTKCytokinetics Announces Three Presentations to Occur at the European Society of Cardiology Heart Failure 2021 Congress
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at Heart Failure 2021, an International Congress of the European Society of Cardiology taking place online from June 29, 2021 – July 1, 2021
Read more →CYTKCytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
Top Line Results of METEORIC-HF Expected in Early 2022 Company Plans to Submit NDA in 2H 2021 Based on Positive Results of GALACTIC-HF SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of pati
Read more →CYTKCytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2021 ALS Roundtables and
Read more →CYTKCytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology
SOUTH SAN FRANCISCO, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) asses
Read more →CYTKCytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
SOUTH SAN FRANCISCO, Calif., May 16, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records related to heart failure (HF) and hypertrophic cardiomyopathy (HCM) were shared in
Read more →CYTKCytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21) taking place online from May 15, 2021 - May 17, 2021. In
Read more →CYTKCytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE, an open-label extension clinical study designed to assess the long-term safety and
Read more →CYTKCytokinetics Reports First Quarter 2021 Financial Results
Secondary Analysis from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session at ACC.21 Company Plans to Submit NDA for Omecamtiv Mecarbil following Recent Meeting with FDA Results from REDWOOD-HCM Expected Mid-Year; Open Label Extension Study and Phase 3 Clinical
Read more →CYTKCytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to Enrollment
SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 cli
Read more →CYTKCytokinetics to Announce First Quarter Results on May 6, 2021
SOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will
Read more →CYTKCytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting
SOUTH SAN FRANCISCO, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data related to the optimization of CK-3773274 (CK-274), including the first disclosure of its chemical structure, were presented at the American Chemica
Read more →CYTKCytokinetics to Participate in the 20th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 20th Annual Needham Virtual Healthca
Read more →CYTKCytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting
SOUTH SAN FRANCISCO, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discovery and key optimization parameters, will be presented at the American Chemical
Read more →CYTKCytokinetics Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) ass
Read more →CYTKCytokinetics Reports Fourth Quarter 2020 Financial Results
Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF Enrollment Completed in Cohort 2 of REDWOOD-HCM; Results Expected Mid-Year Company Provides 2021 Financial Guidance; More Than Two Years of Cash Runway SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWS
Read more →CYTKCytokinetics Names Muna Bhanji to Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Muna Bhanji has been appointed to the company’s Board of Directors. Ms. Bhanji brings more than 30 years of strategic and operational experience in the bi
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on February 25, 2021
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 25, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management
Read more →CYTKCytokinetics Announces Recipients of Third Annual Communications Fellowship Grants
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its third annual Communications Fellowship Grant program, intended to support increased capacity in communications, awareness building and co
Read more →CYTKCytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced that the first patient has been dosed in Cohort 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase
Read more →CYTKCytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-3773274 (CK-274) for the treatment of symptomatic hypertrophic cardi
Read more →CYTKCytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Virtu
Read more →CYTKCytokinetics Regains European Rights to Omecamtiv Mecarbil
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that Amgen Inc. (“Amgen”) notified the company that Les Laboratoires Servier and Institut de Recherches Internationales Servier (“Servier”) elected to terminate the
Read more →CYTKCytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data relating to the impact of patient characteristics on treatment effect in FORTITUDE-ALS, the Phase 2 clinical trial of reldesemtiv in patie
Read more →CYTKCytokinetics Announces Progression of REDWOOD-HCM to Cohort 2
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the progression of REDWOOD-HCM following the conduct of an interim analysis of data from Cohort 1. REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in
Read more →CYTKCytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists
Supplemental Analyses of Primary Composite Endpoint Further Demonstrate Effect of Omecamtiv Mecarbil In Patients with Lower Ejection Fraction SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional
Read more →CYTKCytokinetics Announces Three Presentations at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/MND taking place online from December 9 – December 11, 2020. Title: A Phase 3, Multi-Cen
Read more →CYTKCytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event d
Read more →CYTKCytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen
Company Committed to Advancing Omecamtiv Mecarbil with Initial Focus on Preparations for Regulatory Interactions Following Positive Results of GALACTIC-HF Company to Host Conference Call and Webcast Today at 8:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 23, 2020 (GLOBE
Read more →CYTKCytokinetics Names Nancy Wysenski to Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Nancy Wysenski has been appointed to the company’s Board of Directors. Ms. Wysenski brings more than 25 years of experience in the biopharmaceutical indus
Read more →CYTKCytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records related to heart failure and hypertrophic cardiomyopathy (HCM) were shared in thre
Read more →CYTKCytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data for CK-3773274 (CK-274) and CK-3772271 (CK-271) were shared in poster presentations at the American Heart Association (AHA) Scientific Se
Read more →CYTKCytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medicine
Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death Effect of Omecamtiv Mecarbil Consistent Across Most Prespecified Subgroups with Potentially Greater Tre
Read more →CYTKCytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Cytokinetics to Host Investor/Media Event and Webcast Related to GALACTIC-HF Results on November 13, 2020 at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cytoki
Read more →CYTKCytokinetics Reports Third Quarter 2020 Financial Results
Topline Results From GALACTIC-HF Show Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events; Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Primary results from GALACTIC-HF to be presented as Late Breaking
Read more →CYTKCytokinetics to Announce Third Quarter Results on November 4, 2020
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2020 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management w
Read more →CYTKCytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020
Real-World Population Representative of Patients Enrolled in GALACTIC-HF Indicate a High-Need, High-Risk Population with Heart Failure New Results from COSMIC-HF Show Treatment with Omecamtiv Mecarbil Associated with Improved Right Ventricular Function SOUTH SAN FRANCISCO, Cali
Read more →CYTKCytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure
Heart Failure Patients in Phase 3 Clinical Trial of Omecamtiv Mecarbil Are at High Risk of Cardiovascular Events and Symptom Burden SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that a manuscript detailin
Read more →CYTKCytokinetics Announces Data to Be Presented at the HFSA Virtual Annual Scientific Meeting 2020
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data will be presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020 taking place online from September 30, 2
Read more →CYTKCytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals
Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 13th, 2020 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK)
Read more →CYTKCytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271 (CK-271). CK-271 is a second c
Read more →CYTKCytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 pivotal cardiovascular o
Read more →CYTKCytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced a $1 million grant and four-year partnership with the HCM Registry (HCMR), a global registry of patients with hypertrophic cardiomyopathy (HCM) focused on impro
Read more →CYTKCytokinetics Reports Second Quarter 2020 Financial Results
Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capital to Support Commercial Development and Pipeline Expansion; Company Expects to End 2020 With More Than $500 Million Cash SOUTH SAN FRANC
Read more →CYTKCytokinetics to Announce Second Quarter Results on August 6, 2020
SOUTH SAN FRANCISCO, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2020 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wi
Read more →CYTKCytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today’s Virtual Investor & Analyst Day
Topline Results from GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil, Cardiac Myosin Activator, Expected in Q4 Licensing Collaboration and Royalty Monetization Deals with Xi Jing Pharmaceuticals and RTW Investments Accelerate and Expand Development of CK-3773274, Next
Read more →CYTKCytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
$250 Million in Committed Capital to Cytokinetics; Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing Pharmaceuticals to Develop & Commercialize in China RTW Provides Access to Capital to Cytokinetics to Fund Global Development in Exchange
Read more →CYTKCytokinetics Announces Participation in the Launch of Kainomyx, Inc. Focused to the Treatment of Parasitic Diseases
SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is participating in the launch of Kainomyx, Inc., a new biopharmaceutical company focused on the discovery and development of small molecule therapeuti
Read more →CYTKCytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
SOUTH SAN FRANCISCO, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a Virtual Investor and Analyst Day on Wednesday, July 15, 2020 from 8:30 AM to 11:30 AM ET. Members of Cytokinetics’ senior management will
Read more →CYTKCytokinetics to Participate In Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.,, June 08, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Goldman Sachs 41st Annual Global Heal
Read more →CYTKCytokinetics Reports First Quarter 2020 Financial Results
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN FRANCISCO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first q
Read more →CYTKCytokinetics to Announce First Quarter Results on May 6, 2020
SOUTH SAN FRANCISCO, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2020 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will
Read more →CYTKCytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic
SOUTH SAN FRANCISCO, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today provided an update regarding the company's clinical trials and business operations related to its response to the COVID-19 pandemic alongside its commitment to prioriti
Read more →CYTKCytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 19th Annual Needham Virtual Healthcar
Read more →CYTKCytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual
SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that patient baseline characteristics and demographics from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility
Read more →CYTKCYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC
SOUTH SAN FRANCISCO, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that patient baseline characteristics and demographics from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility i
Read more →CYTKCytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the treatment of amyotrophic lateral sclerosis (A
Read more →CYTKCytokinetics Reports Fourth Quarter 2019 Financial Results
GALACTIC-HF Continuing Following Second Planned Interim Analysis; Top-line Results for GALACTIC-HF Expected in Q4 2020 Company Provides 2020 Financial Guidance; More Than Two Years of Cash Runway Based on 2020 Guidance SOUTH SAN FRANCISCO, Calif., March 03, 2020 (GLOBE NEWSWI
Read more →CYTKCytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure
In Vitro Studies Demonstrate Cardiac Troponin Activator Selectively Activates Cardiac Muscle Fibers with Little Effect on Slow Skeletal Muscle or Fast Skeletal Muscle Expect to Complete SAD/MAD Phase 1 Study of AMG 594 in 2H 2020 SOUTH SAN FRANCISCO, Calif., March 03, 2020 (GLO
Read more →CYTKCytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data related to CK-3773274 (CK-274) were presented at the Biophysical Society 64th Annual Meeting in San Diego, CA elaborating on its mechanis
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on March 3, 2020
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wil
Read more →CYTKCytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Second Interim Analysis in GALACTIC-HF Expected to Occur in Q1 2020 Topline Results Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the publication of a manuscript relating to the desig
Read more →CYTKCytokinetics Announces Recipients of Second Annual Communications Fellowship Grants
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced the recipients of its Communications Fellowship Grant program, an annual grant program intended to support increased capacity in communications, awareness building and
Read more →CYTKCytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor Planned to Enter Clinic in 1H 2020 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) to
Read more →CYTKCytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) has opened to enrollment. REDWOOD-HCM is a Phase 2 clinica
Read more →CYTKCytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS). P
Read more →CYTKCytokinetics Announces New Results Presented at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new results were presented at the 30th International Symposium on ALS/MND in Perth, Australia, including additional analyses from FORTITUDE-ALS (Functiona
Read more →CYTKCytokinetics to Participate in the Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research & Development, is scheduled to participate in a fireside chat at the 31st Annual Piper Jaff
Read more →CYTKCytokinetics Announces Five Presentations at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five poster presentations at the 30th International Symposium on ALS/MND in Perth, Australia. The posters will be presented on Thursday, December 5, 2019 and F
Read more →CYTKCytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2019
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamti
Read more →CYTKCytokinetics Announces Pricing of Public Offering of Convertible Senior Notes
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it has agreed to sell an aggregate of $120.0 million principal amount of its 4.00% convertible senior notes due 2026, or the notes, in an underwritten pub
Read more →CYTKCytokinetics Announces Proposed Public Offering of Convertible Senior Notes
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it expects to sell, subject to market and other conditions, an aggregate of $100.0 million principal amount of its convertible senior notes due 2026, or t
Read more →CYTKCytokinetics to Participate in the Credit Suisse 28th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research & Development, is scheduled to participate in the Credit Suisse 28th Annual Healthcare Conf
Read more →CYTKCytokinetics Reports Third Quarter 2019 Financial Results
Enrollment Completed in GALACTIC-HF with More than 8,200 Heart Failure Patients; Second Interim Analysis Expected in Q1 2020 Data from Phase 1 Study of CK-274 Support Progression; Phase 2 Clinical Trial in Patients with Obstructive Hypertrophic Cardiomyopathy to Begin in Q4 20
Read more →CYTKCytokinetics to Announce Third Quarter Results on October 31, 2019
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on October 31, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wi
Read more →CYTKCytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional analyses of FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints
Read more →CYTKCytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Cantor Fitzgerald Global Healthcare Conference o
Read more →CYTKCytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in En
Read more →CYTKCytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals
Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular or Neuromuscular Diseases Deadline for Applications is November 15th, 2019 SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK)
Read more →CYTKCytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two poster presentations at the 23rd Annual Heart Failure Society of America (HFSA) Scientific Meeting in Philadelphia. The posters will be presented on Septe
Read more →CYTKCytokinetics to Present at September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: 17th Annual Mor
Read more →CYTKCytokinetics Reports Second Quarter 2019 Financial Results
Completed Enrollment in GALACTIC-HF with More than 8,200 Heart Failure Patients Results from Phase 1 Study of CK-274 to be Presented at HFSA in September 2019; Phase 2 Clinical Trial Expected to Begin in Q4 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cytokine
Read more →CYTKCytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
Preclinical Studies Show CK-3773274 Produces Exposure Related Effects on Cardiac Contractility in Healthy Animals and Mouse Models of Hypertrophic Cardiomyopathy and Support Therapeutic Hypothesis for Onset of Action and Reversibility in the Clinical Setting SOUTH SAN FRANCISCO,
Read more →CYTKCytokinetics to Announce Second Quarter Results on August 8, 2019
SOUTH SAN FRANCISCO, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on August 8, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wil
Read more →CYTKCytokinetics Announces Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics
SOUTH SAN FRANCISCO, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the publication of data in The Journal of Physiology demonstrating that a fast skeletal muscle troponin activator (FSTA) can decrease skeletal muscle fatigue b
Read more →CYTKCytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy
SOUTH SAN FRANCISCO, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of spinal muscular atrophy
Read more →CYTKCytokinetics Announces Preclinical Data Relating to CK-3773274 to be Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
SOUTH SAN FRANCISCO, Calif., July 22, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that two preclinical poster presentations relating to CK-3773274 (CK-274) will be presented at the American Heart Association’s Basic Cardiovascular Sciences (
Read more →CYTKCytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
SOUTH SAN FRANCISCO, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), th
Read more →CYTKCytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference
Two Studies Show Addition of Reldesemtiv to SMN-Directed Treatment Increases Muscle Force in Mouse Model of Spinal Muscular Atrophy SOUTH SAN FRANCISCO, Calif., June 28, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from two preclin
Read more →CYTKCytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference
SOUTH SAN FRANCISCO, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that two preclinical poster presentations on the addition of reldesemtiv to treatment with SMN upregulators (nusinersen and SMN-C1, an analogue to risdiplam) wi
Read more →CYTKCytokinetics to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesd
Read more →CYTKCytokinetics Reports First Quarter 2019 Financial Results
GALACTIC-HF Continues Following Interim Analysis for Futility; METEORIC-HF Opened to Enrollment Phase 1 Data for CK-274 Expected in Q3 2019; Planning Underway for Potential Progression to Phase 2 FORTITUDE-ALS Demonstrates Patients on All Doses of Reldesemtiv Declined Less Th
Read more →CYTKCytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
Trial Did Not Meet Statistical Significance for Primary Efficacy Analysis Patients on All Doses of Reldesemtiv Declined Less Than Patients on Placebo for SVC and ALSFRS-R, With Clinically Meaningful Differences Emerging Over Time Early Terminations and Serious Adverse Events
Read more →CYTKCytokinetics to Announce First Quarter Results on May 9, 2019
SOUTH SAN FRANCISCO, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on May 9, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will h
Read more →CYTKCytokinetics to Present at April Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: H.C. Wainwright
Read more →CYTKCytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19
SOUTH SAN FRANCISCO, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecam
Read more →CYTKCytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19
SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecam
Read more →CYTKCytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that results from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – i
Read more →CYTKCytokinetics Joins Global Initiative To Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is standing with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disea
Read more →CYTKCytokinetics Reports Fourth Quarter 2018 Financial Results
Company Provides 2019 Financial Guidance and Expected Milestones Reduced Operating Expenses vs. 2018; Over Two Years of Cash Based on Current Burn Rate Interim Analysis for GALACTIC-HF on Track for 1H 2019 Results from FORTITUDE-ALS Expected in Q2 2019 SOUTH SAN FRANCISCO, Ca
Read more →CYTKCytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safe
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on February 21, 2019
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on February 21, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management
Read more →CYTKCytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that the Six Minute Walk Test (6MWT) is an acceptable primary efficacy endpoint
Read more →CYTKCytokinetics Announces New Data Presented at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK, including patient baseline characteristics and demographi
Read more →CYTKCytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple ascending dose clinical trial of CK
Read more →CYTKCytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Dec
Read more →CYTKCytokinetics, Inc. Reports Third Quarter 2018 Financial Results
METEORIC-HF Advancing to Trial Initiation FORTITUDE-ALS on Track to Complete Enrollment by Year End Phase 1 Clinical Studies of CK-274 and AMG 594 To Start in Q4 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported f
Read more →CYTKCytokinetics to Announce Third Quarter Results on November 1, 2018
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on November 1, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wi
Read more →CYTKCytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day
Investigational New Drug Applications Recently Filed for Two New Cardiac Programs: Cardiac Troponin Activator and Cardiac Myosin Inhibitor Advance Toward Phase 1 Studies Clinical Trial Design Announced for METEORIC-HF, the Second Phase 3 Trial of Omecamtiv Mecarbil Phase 2 Clin
Read more →CYTKCytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program
SOUTH SAN FRANCISCO, Calif., and TOKYO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update for their collaborative skeletal muscle program, including clinical trial
Read more →CYTKCytokinetics to Host R&D Day on October 16, 2018
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host an R&D Day on Tuesday, October 16, 2018 from 8:30 AM to 12:30 PM ET at the Parker New York Hotel in New York City. Members of Cytokinetics’
Read more →CYTKCytokinetics to Present at the Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16th Annual Morgan Stanley Global Healthcare Conference
Read more →CYTKCytokinetics Awards Inaugural Communications Fellowship To The ALS Association Golden West Chapter
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that The ALS Association Golden West Chapter is the inaugural recipient of the Cytokinetics Communications Fellowship, an annual grant from the company intende
Read more →CYTKCytokinetics, Inc. Reports Second Quarter 2018 Financial Results
Phase 2 Study of Reldesemtiv in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure Results from Phase 2 Clinical Trial of Reldesemtiv in Patients with COPD Expected in Q3 Finalizing Preparations to In
Read more →CYTKCytokinetics to Announce Second Quarter Results on July 26, 2018
SOUTH SAN FRANCISCO, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will
Read more →CYTKCytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference
SOUTH SAN FRANCISCO, Calif., June 16, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) were presented in an oral presentation by John W. Day, M.D.,
Read more →CYTKCytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018
SOUTH SAN FRANCISCO, Calif., June 08, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 An
Read more →CYTKCytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA
ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics today announced an expanded partnership to increase education, awareness and fundraising for spinal muscular atrophy (SMA). As a National Platinum Partner for 2018
Read more →CYTKCytokinetics, Inc. Reports First Quarter 2018 Financial Results
Completed Enrollment in Phase 2 Study of Reldesemtiv in Patients with SMA; Data Expected in Q2 2018 Preparing to Initiate Second Phase 3 Clinical Trial of Omecamtiv Mecarbil SOUTH SAN FRANCISCO, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK
Read more →CYTKCytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference
SOUTH SAN FRANCISCO, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented by John Day, M.D., Ph.D., Professor o
Read more →CYTKCytokinetics to Announce First Quarter Results on April 26, 2018
SOUTH SAN FRANCISCO, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on April 26, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wil
Read more →CYTKCytokinetics to Present at March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: Cowen and Compan
Read more →CYTKCytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
Company Provides 2018 Financial Guidance and Expected Milestones; Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate CK-2127107 Advancing in Four Clinical Trials Under Collaboration with Astellas; Results Expected in 2018 with Data from Phas
Read more →CYTKCytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the RBC Capital Markets Global Healthcare Conference on Thursd
Read more →CYTKCytokinetics Names Robert Califf, M.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert Califf, M.D., has been appointed to the company’s Board of Directors. Dr. Califf is the Vice Chancellor for Health Data Science at Duke Health and D
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on February 15, 2018
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on February 15, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management
Read more →CYTKCytokinetics Announces Progress Against Vision 2020
Multiple Clinical Trials Advance Under Collaborations with Astellas and Amgen Results from Four Clinical Trials of CK-2127107 Expected in 2018 Pipeline Expands with Three New Programs Advancing from Muscle Biology Research to Development SOUTH SAN FRANCISCO, Calif., Jan. 03,
Read more →CYTKCytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND
Previously Announced Results from Phase 3 Clinical Trial of Tirasemtiv Shared with ALS Community VITALITY-ALS Did Not Meet Primary or Secondary Endpoints Trial Informs Development of Next Generation Drug Candidate SOUTH SAN FRANCISCO, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) --
Read more →CYTKCytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the results from VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS), the inter
Read more →CYTKCytokinetics Announces Negative Results From VITALITY-ALS
Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS Did Not Meet Primary or Secondary Endpoints Results to be Presented December 8th at 28th International Symposium on ALS/MND Conference Call Today at 8:30 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 21, 2017 (GL
Read more →CYTKCytokinetics Announces Additional Results From COSMIC-HF at the American Heart Association Scientific Sessions 2017
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 clinical trial evaluating
Read more →CYTKCytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the American Heart Association Scientific Sessions 2017
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamti
Read more →CYTKCytokinetics, Inc. Reports Third Quarter 2017 Financial Results
VITALITY-ALS Proceeding towards Planned Database Lock and Read-out in Q4; Commercial Planning and Preparations for Potential Regulatory Submissions Underway CK-2127107 Advancing in Four Mid-Stage Clinical Trials Under Collaboration with Astellas First Patient Recently Dosed in
Read more →CYTKCytokinetics to Announce Third Quarter Results on October 26, 2017
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on October 26, 2017 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wi
Read more →CYTKCytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the first patient has been dosed in Japan in GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Fa
Read more →CYTKCytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamt
Read more →CYTKCytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecar
Read more →CYTKCytokinetics, Inc. Reports Second Quarter 2017 Financial Results
Results Expected from VITALITY-ALS, Our Phase 3 Clinical Trial of Tirasemtiv, in Q4 2017 CK-2127107 Advancing in Four Clinical Trials Under Our Collaboration with Astellas Omecamtiv Mecarbil Phase 3 Clinical Trial Proceeding on Plan in GALACTIC-HF Under Our Collaboration with A
Read more →CYTKCytokinetics Announces Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients With Heart Failure
Data Supports Inclusion of Japan in GALACTIC-HF Company is Eligible to Earn $10 Million Milestone Payment from Amgen upon First Patient Dosing in Japan in Phase 3 Outcomes Trial SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CY
Read more →CYTKCytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the start of FORTITUDE-ALS, Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS.
Read more →CYTKCytokinetics to Announce Second Quarter Results on August 2, 2017
SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on Wednesday, August 2, 2017 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management
Read more →CYTKCytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA
SOUTH SAN FRANCISCO, Calif., July 05, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that data relating to patient baseline characteristics and the reasons for patient screen failure, both from the first cohort of the Phase 2 clinical trial of CK-212710
Read more →CYTKCytokinetics Announces Start of Phase 1b Clinical Trial of CK-2127107 in Elderly Subjects With Limited Mobility
SOUTH SAN FRANCISCO, Calif., June 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the start of a Phase 1b, double-blind, randomized, placebo-controlled, multiple dose, two-period crossover study to assess the effect of CK-2127107 on measures
Read more →CYTKCytokinetics Announces Presentations at the Cure SMA 2017 Annual SMA Conference
SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced presentations at the Cure SMA 2017 Annual SMA Conference from June 29 - July 2, 2017 in Orlando, FL. In an oral presentation on July 1, Stacy Rudnicki, M.D., Di
Read more →CYTKCytokinetics to Participate in Panel on Neuromuscular Disorders at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., June 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a panel discussion on Neuromuscular Disorders at the JMP Securities 2017 Life
Read more →CYTKCytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy
SOUTH SAN FRANCISCO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-2127107 for the potential
Read more →CYTKCytokinetics Announces Results from Dose Escalation Phase of COSMIC-HF Presented at Heart Failure 2017
SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that results from the dose escalation phase of COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating
Read more →CYTKCytokinetics, Inc. Reports First Quarter 2017 Financial Results
Data Monitoring Committee for VITALITY-ALS Recommended Continuation of Phase 3 Trial; Results Expected in Q4 Sale of Royalty on Omecamtiv Mecarbil to Royalty Pharma Contributed to Increased Cash Balance Expansion of Clinical Trials Program for CK-2127107 in Collaboration with
Read more →CYTKCytokinetics Added to S&P SmallCap 600
SOUTH SAN FRANCISCO, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- Cytokinetics (Nasdaq:CYTK) today announced it has been selected for addition to the S&P SmallCap 600 GICS Biotechnology Sub-Industry Index. The index, a member of the Dow Jones Total Stock Market Indices family, is d
Read more →CYTKCytokinetics to Announce First Quarter Results on April 27, 2017
SOUTH SAN FRANCISCO, Calif., April 13, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on Thursday, April 27, 2017 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management w
Read more →CYTKCytokinetics to Present at the 16th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16th Annual Needham Healthcare Conference on Wednesday, A
Read more →CYTKCytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy
Data Monitoring Committee Agrees to Proceed to Higher Dose Cohort One of Four Clinical Trials in 2017 under Astellas Collaboration SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that the second cohort of the Phas
Read more →CYTKCytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference
SOUTH SAN FRANCISCO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that preclinical data for CK-2127107 were presented at the MDA Scientific Conference in Arlington, VA, showing that this next-generation fast skeletal troponin activat
Read more →CYTKCytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17
SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecar
Read more →CYTKCytokinetics Announces Presentation of Additional Results from COSMIC-HF at ACC.17
SOUTH SAN FRANCISCO, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecar
Read more →CYTKCytokinetics, Inc. Reports Fourth Quarter 2016 Financial Results
Company Provides 2017 Financial Guidance and Expected Milestones Phase 3 Results Expected from VITALITY-ALS in Q4 2017 SOUTH SAN FRANCISCO, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total revenues for the fourth quarter of 2016 were $33
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on February 16, 2017
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on Thursday, February 16, 2017 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior managemen
Read more →CYTKCytokinetics and Royalty Pharma Announce $100 Million Transaction for Omecamtiv Mecarbil
Royalty Pharma Buys 4.5 Percent Royalty on Worldwide Sales for $90 Million Plus $10 Million Equity in Cytokinetics Cytokinetics Agrees to Exercise Option to Co-Fund Phase 3 Development Program Under Collaboration with Amgen for Increased Royalty and Co-Promotion Rights in Nort
Read more →CYTKCytokinetics Added to Nasdaq Biotechnology Index
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Cytokinetics (Nasdaq:CYTK) today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI). The addition will take effect as part of the annual re-ranking of the NBI upon market open o
Read more →CYTKCytokinetics Announces Presentations at the International Symposium on ALS/MND
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced one oral presentation and two poster presentations at the 27th International Symposium on ALS/MND in Dublin, Ireland. The posters will be presented on Wednesday, Decemb
Read more →CYTKCytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil
Trial to be Conducted Under Special Protocol Assessment with the FDA Company Earns $26.7 Million Milestone Payment from Amgen SOUTH SAN FRANCISCO, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the activation of the first clinical sit
Read more →CYTKCytokinetics Announces Presentation of Additional Results From COSMIC-HF at the AHA Annual Scientific Meeting
Data Show Omecamtiv Mecarbil Improved Measures of Left Atrial Structure and Function SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to
Read more →CYTKCytokinetics Announces New Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2016
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, (Nasdaq:CYTK) today announced that a new analysis of left atrial structure and function from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 tria
Read more →CYTKCytokinetics Announces Publication Relating to Novel Smooth Muscle Myosin Inhibitor
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) a leader in muscle biology and the mechanics of muscle performance, today announced the publication of preclinical data characterizing a smooth muscle myosin (SMM) inhibitor that induc
Read more →CYTKCytokinetics, Inc. Reports Third Quarter 2016 Financial Results
Omecamtiv Mecarbil Advancing to Phase 3 With Agreement from FDA on Key Elements of Special Protocol Assessment VIGOR-ALS Enrolling Patients with ALS Who Have Completed VITALITY-ALS $65 Million Recently Received From Astellas Related to Expanded Collaboration SOUTH SAN FRANCIS
Read more →CYTKCytokinetics Announces First Patient Enrolled in VIGOR-ALS, an Open-Label Extension Clinical Trial of Tirasemtiv
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the first patient has been enrolled in VIGOR-ALS (Ventilatory Investigations in Global Open-Label Research in ALS), an open-label extension clinical trial designed to a
Read more →CYTKCytokinetics to Announce Third Quarter Results on October 27, 2016
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on Thursday, October 27, 2016 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management
Read more →CYTKCytokinetics Announces Early Termination of Hart-Scott-Rodino Waiting Period for Expanded Collaboration With Astellas
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in conne
Read more →CYTKCytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecar
Read more →CYTKCytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecar
Read more →CYTKCytokinetics Announces Next-Generation Fast Skeletal Muscle Activator Entering IND-Enabling Studies
Triggers Milestone Payment from Astellas; Expands Portfolio of Skeletal Muscle Activators SOUTH SAN FRANCISCO, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the initiation of IND-enabling studies for a next-generation fast skeletal
Read more →CYTKCytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the advancement of omecamtiv mecarbil to Phase 3 clinical development with a cardiovascular outcomes clinical trial expected to initiate in the fourth quarter of 2016.
Read more →CYTKCytokinetics Completes Enrollment in VITALITY-ALS, Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the completion of patient enrollment in VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS),
Read more →CYTKCytokinetics, Inc. Reports Second Quarter 2016 Financial Results
Company Recently Announced Option Right for Tirasemtiv and Expansion of Global Collaboration for CK-2127107 in ALS with Astellas Nearing Completion of Patient Enrollment in VITALITY-ALS SOUTH SAN FRANCISCO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:C
Read more →CYTKCytokinetics and Astellas Announce Option Right for Tirasemtiv and Expansion of Global Collaboration for CK-2127107 in ALS
SOUTH SAN FRANCISCO, Calif. and TOKYO, July 27, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) (“Cytokinetics”) and Astellas Pharma Inc. (TSE:4503) (“Astellas”) today announced that Cytokinetics and Astellas have expanded their collaboration in skeletal muscle activato
Read more →CYTKCytokinetics to Announce Second Quarter Results on July 28, 2016
SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report second quarter results on Thursday, July 28, 2016 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management wi
Read more →CYTKCytokinetics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Tuesda
Read more →CYTKCytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Chronic Obstructive Pulmonary Disease
SOUTH SAN FRANCISCO, Calif., June 30, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a randomized, double-blind, placebo-controlled, two period crossover clinical trial designed to assess the effect of CK-2127107 (CK-107) on physical functi
Read more →CYTKCytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress
Treatment with Omecamtiv Mecarbil Produced Progressive and Sustained Effects On Cardiac Function as Measured by Reductions in Diastolic Ventricular Volume and NT-proBNP SOUTH SAN FRANCISCO, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced
Read more →CYTKCytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif., May 20, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company’s Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medic
Read more →CYTKCytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016
SOUTH SAN FRANCISCO, Calif., May 13, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, (Nasdaq:CYTK) announced today that a poster presentation on additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2b trial evaluat
Read more →CYTKCytokinetics to Ring Nasdaq Closing Bell to Launch ALS Awareness Month
SOUTH SAN FRANCISCO, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it will ring the Closing Bell at Nasdaq this afternoon in recognition of ALS Awareness Month and the company’s commitment to education, awareness, research and deve
Read more →CYTKCytokinetics, Inc. Reports First Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the first quarter of 2016 were $8.4 million, compared to $4.4 million, during the same period in 2015. The net loss for the first
Read more →CYTKCytokinetics to Announce First Quarter Results on April 28, 2016
SOUTH SAN FRANCISCO, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 28, 2016 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management w
Read more →CYTKCytokinetics to Present at the 15th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 15th Annual Needham Healthcare Conference on Tuesday, Apr
Read more →CYTKCytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure
SOUTH SAN FRANCISCO, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the start of a double-blind, randomized, placebo-controlled, multi-center Phase 2 clinical trial to evaluate the safety, pharmacokinetics and efficacy of omecamtiv mec
Read more →CYTKCytokinetics Joins Global Movement to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is joining forces with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to raise awareness of Rare
Read more →CYTKCytokinetics, Inc. Reports Fourth Quarter 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the fourth quarter of 2015 were $9.8 million, compared to $21.8 million, which included a $15 million milestone payment from Astell
Read more →CYTKCytokinetics to Announce Fourth Quarter Results on February 16, 2016
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report fourth quarter results on Tuesday, February 16, 2016 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management
Read more →CYTKCytokinetics Outlines Vision 2020 Strategic Initiative to Advance Portfolio of Muscle Biology Drug Candidates
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today outlined Vision 2020: Empowering Our Future, a strategic initiative designed to deepen and expand its pipeline over the next five years as well as advance a portfolio of muscle-b
Read more →CYTKCytokinetics Presents Analyses Demonstrating Predictive Value of Slow Vital Capacity for Clinical Outcomes in ALS
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced the presentation of exploratory analyses of data from EMPOWER, a Phase 3 clinical trial of dexpramipexole in patients with ALS, which demonstrated the rate of decline o
Read more →CYTKCytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that its first Phase 2 clinical trial of CK-2127107, a novel fast skeletal muscle troponin activator, in patients with spinal muscular atrophy (SMA) has opened to enrol
Read more →CYTKCytokinetics to Present at 27th Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December
Read more →CYTKCytokinetics Announces Results From COSMIC-HF to be Presented in Late Breaking Clinical Trial Session at American Heart Association Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Cytokinetics Incorporated (NASDAQ:CYTK) today announced that results from the expansion phase of COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluati
Read more →CYTKCytokinetics, Inc. Reports Third Quarter 2015 Financial Results
Recently Announced Positive Top-line Results From COSMIC-HF; Data Demonstrated Statistically Significant Improvements in Several Pre-Specified Measures of Cardiac Function Company Lowers 2015 R&D Expense Guidance SOUTH SAN FRANCISCO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Cy
Read more →CYTKCytokinetics to Announce Third Quarter Results on October 29, 2015
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 29, 2015 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management
Read more →CYTKCytokinetics, Inc. Reports Second Quarter 2015 Financial Results
Company Recently Started VITALITY-ALS; Results from COSMIC-HF Expected in Q4 Company Updates Financial Guidance for 2015 SOUTH SAN FRANCISCO, Calif., July 29, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total research and development revenues for the seco
Read more →CYTKCytokinetics to Announce Second Quarter Results on July 29, 2015
SOUTH SAN FRANCISCO, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) announced today that it is scheduled to report second quarter results on Wednesday, July 29, 2015 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management w
Read more →CYTKCytokinetics and the ALS Association Announce Awarding of Grant for Phase 3 Clinical Trial and Biomarker Research Collaboration
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, DC, July 14, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc., (Nasdaq:CYTK) and The ALS Association today announced that The Association has awarded Cytokinetics a $1.5 million grant to support the collection of clinical data and plasma sam
Read more →CYTKCytokinetics Announces Start of Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS
SOUTH SAN FRANCISCO, Calif., July 14, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK), a leading muscle biology company, today announced the start of VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year
Read more →CYTKCytokinetics Presents Results From Phase I Studies of CK-2127107
SOUTH SAN FRANCISCO, Calif., June 19, 2015 (GLOBE NEWSWIRE) -- Cytokinetics (Nasdaq:CYTK) announced today that results from three double-blind, randomized, placebo-controlled Phase I studies of CK-2127107 in healthy volunteers were presented in a poster at the 19th International
Read more →CYTKCytokinetics to Present at the 9th Annual JMP Securities Life Sciences Conference 2015
SOUTH SAN FRANCISCO, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 9th Annual JMP Securities Life Sciences Conference
Read more →CYTKCytokinetics Announces Poster Presentation on CK-2127107 at the 19th International SMA Researcher Meeting
SOUTH SAN FRANCISCO, Calif., June 11, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, (Nasdaq:CYTK) announced today that a poster presentation on the company’s fast skeletal muscle activator, CK-2127107, will be presented at the 19th International SMA Researcher Meeting to be held during
Read more →CYTKCytokinetics and The ALS Association Announce Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. and WASHINGTON D.C., June 4, 2015 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as wel
Read more →CYTKCytokinetics, Incorporated Reports First Quarter 2015 Financial Results
Company is Readying to Initiate a Phase III Clinical Trial of Tirasemtiv in Patients With ALS following Recent Meetings With FDA and EMA Completion of Patient Enrollment in COSMIC-HF Enable Results Expected Later This Year SOUTH SAN FRANCISCO, Calif., April 30, 2015 (GLOBE NEWS
Read more →Competitive Position
How CYTK ranks across every disease it competes inCompetitive Position is a premium feature
See how CYTK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial